CA3222853A1 - Composition cosmetique solaire contenant des acides amines analogues de la mycosporine - Google Patents
Composition cosmetique solaire contenant des acides amines analogues de la mycosporine Download PDFInfo
- Publication number
- CA3222853A1 CA3222853A1 CA3222853A CA3222853A CA3222853A1 CA 3222853 A1 CA3222853 A1 CA 3222853A1 CA 3222853 A CA3222853 A CA 3222853A CA 3222853 A CA3222853 A CA 3222853A CA 3222853 A1 CA3222853 A1 CA 3222853A1
- Authority
- CA
- Canada
- Prior art keywords
- organic
- composition according
- group
- composition
- screening agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 154
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 13
- 239000002537 cosmetic Substances 0.000 title description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 183
- 238000012216 screening Methods 0.000 claims abstract description 176
- 230000005855 radiation Effects 0.000 claims abstract description 18
- -1 methoxyphenylimino dimethylcyclohexene Chemical compound 0.000 claims description 111
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 52
- 150000001875 compounds Chemical class 0.000 claims description 38
- 239000004471 Glycine Substances 0.000 claims description 27
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 claims description 22
- SQPWWRYFUFYMJW-UHFFFAOYSA-N CCCCCCCC(OC1(C(O)=O)N(NC2=CC=CC=C2)SC2=CC=CCC2C1(C)C)=O Chemical compound CCCCCCCC(OC1(C(O)=O)N(NC2=CC=CC=C2)SC2=CC=CCC2C1(C)C)=O SQPWWRYFUFYMJW-UHFFFAOYSA-N 0.000 claims description 20
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 claims description 18
- 229960005193 avobenzone Drugs 0.000 claims description 17
- 230000037072 sun protection Effects 0.000 claims description 17
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 claims description 16
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 claims description 16
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 claims description 14
- 229960004881 homosalate Drugs 0.000 claims description 13
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000004224 protection Effects 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 7
- 125000004185 ester group Chemical group 0.000 claims description 6
- 229960003921 octisalate Drugs 0.000 claims description 6
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 claims description 6
- CENPSTJGQOQKKW-UHFFFAOYSA-N 2,4,6-tris(4-phenylphenyl)-1,3,5-triazine Chemical compound C1=CC=CC=C1C1=CC=C(C=2N=C(N=C(N=2)C=2C=CC(=CC=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC=CC=2)C=C1 CENPSTJGQOQKKW-UHFFFAOYSA-N 0.000 claims description 5
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims description 5
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 5
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 claims description 5
- 229940068171 ethyl hexyl salicylate Drugs 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 229960001679 octinoxate Drugs 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 claims description 4
- ZUZFYDYPRGBMKI-UHFFFAOYSA-N [6-[4-[2-benzoyl-4-(diethylamino)-3-hydroxybenzoyl]piperazine-1-carbonyl]-3-(diethylamino)-2-hydroxyphenyl]-phenylmethanone Chemical compound C(C)N(CC)C1=C(C(=C(C(=O)N2CCN(CC2)C(C2=C(C(=C(C=C2)N(CC)CC)O)C(C2=CC=CC=C2)=O)=O)C=C1)C(C1=CC=CC=C1)=O)O ZUZFYDYPRGBMKI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- GLCJMPWWQKKJQZ-UHFFFAOYSA-L disodium;2-[4-(4,6-disulfonato-1h-benzimidazol-2-yl)phenyl]-1h-benzimidazole-4,6-disulfonate;hydron Chemical compound [Na+].[Na+].C1=C(S(O)(=O)=O)C=C2NC(C3=CC=C(C=C3)C3=NC4=C(C=C(C=C4N3)S(=O)(=O)O)S([O-])(=O)=O)=NC2=C1S([O-])(=O)=O GLCJMPWWQKKJQZ-UHFFFAOYSA-L 0.000 claims description 4
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 4
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 claims description 3
- GNWOUAREWAECCV-UHFFFAOYSA-N 4,7,7-trimethyl-2-[(3-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound CC1=CC=CC(C=C2C(C3(CCC2C3(C)C)C)=O)=C1 GNWOUAREWAECCV-UHFFFAOYSA-N 0.000 claims description 3
- VVTDHOIRNPCGTH-UHFFFAOYSA-N Mycosporin 1 Natural products COC1=C(NC(CO)CO)CC(O)(CO)CC1=O VVTDHOIRNPCGTH-UHFFFAOYSA-N 0.000 claims description 3
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 claims description 3
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 claims description 3
- 229960002709 amiloxate Drugs 0.000 claims description 3
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 3
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 claims description 3
- 229960000655 ensulizole Drugs 0.000 claims description 3
- 229960004697 enzacamene Drugs 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000601 octocrylene Drugs 0.000 claims description 3
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 3
- 229960001173 oxybenzone Drugs 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000368 sulisobenzone Drugs 0.000 claims description 3
- 239000004721 Polyphenylene oxide Chemical class 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 229940111759 benzophenone-2 Drugs 0.000 claims description 2
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229920000570 polyether Chemical class 0.000 claims description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000005313 fatty acid group Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 101150018863 maa gene Proteins 0.000 description 55
- 239000000284 extract Substances 0.000 description 28
- 239000002994 raw material Substances 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 229920001577 copolymer Polymers 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 8
- 241000209140 Triticum Species 0.000 description 8
- 235000021307 Triticum Nutrition 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 229940100539 dibutyl adipate Drugs 0.000 description 8
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 8
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc oxide Inorganic materials [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 229940015975 1,2-hexanediol Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229940031569 diisopropyl sebacate Drugs 0.000 description 6
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- WHBKVWBGTBULQY-UHFFFAOYSA-N 2-propylheptyl octanoate Chemical compound CCCCCCCC(=O)OCC(CCC)CCCCC WHBKVWBGTBULQY-UHFFFAOYSA-N 0.000 description 5
- UOIBFJBJAWHQNM-JRUKXMRZSA-N N-Oleoyl tyrosine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UOIBFJBJAWHQNM-JRUKXMRZSA-N 0.000 description 5
- 229940116224 behenate Drugs 0.000 description 5
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 5
- 229940081733 cetearyl alcohol Drugs 0.000 description 5
- 239000008406 cosmetic ingredient Substances 0.000 description 5
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 5
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 4
- WAJCJDLRJVDSSD-UHFFFAOYSA-N 2-ethylhexyl 2-cyano-3-(4-methoxyphenyl)-3-phenylprop-2-enoate Chemical group C=1C=C(OC)C=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 WAJCJDLRJVDSSD-UHFFFAOYSA-N 0.000 description 4
- PBFGMXZRJIUGKU-UHFFFAOYSA-N 3-decanoyloxybutyl decanoate Chemical compound CCCCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCCCC PBFGMXZRJIUGKU-UHFFFAOYSA-N 0.000 description 4
- LFESLSYSZQYEIZ-UHFFFAOYSA-N 3-octanoyloxybutyl octanoate Chemical compound CCCCCCCC(=O)OCCC(C)OC(=O)CCCCCCC LFESLSYSZQYEIZ-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- DJNTZVRUYMHBTD-UHFFFAOYSA-N Octyl octanoate Chemical compound CCCCCCCCOC(=O)CCCCCCC DJNTZVRUYMHBTD-UHFFFAOYSA-N 0.000 description 4
- 229940114374 butylene glycol dicaprylate Drugs 0.000 description 4
- 229940083936 c20-22 alcohols Drugs 0.000 description 4
- 229940048300 coco-caprylate Drugs 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 4
- 229940073668 ethylhexyl methoxycrylene Drugs 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 description 4
- CSFWPUWCSPOLJW-UHFFFAOYSA-N lawsone Chemical compound C1=CC=C2C(=O)C(O)=CC(=O)C2=C1 CSFWPUWCSPOLJW-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 229940104349 oleoyl tyrosine Drugs 0.000 description 4
- OSORMYZMWHVFOZ-UHFFFAOYSA-N phenethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCCC1=CC=CC=C1 OSORMYZMWHVFOZ-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 4
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 235000010215 titanium dioxide Nutrition 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 235000014692 zinc oxide Nutrition 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 229940043375 1,5-pentanediol Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- JXPHIHWXMBYJAU-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3,4-dihydrochromen-6-ol Chemical compound O1C(C)(C)CCC2=C1C=C(OC)C(O)=C2 JXPHIHWXMBYJAU-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- SAOKZLXYCUGLFA-UHFFFAOYSA-N bis(2-ethylhexyl) adipate Chemical compound CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC SAOKZLXYCUGLFA-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940117973 dimethylmethoxy chromanol Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 229940100463 hexyl laurate Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229940057429 sorbitan isostearate Drugs 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- PZTAGFCBNDBBFZ-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CO PZTAGFCBNDBBFZ-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940089413 tribehenin peg-20 esters Drugs 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- NRTKYSGFUISGRQ-UHFFFAOYSA-N (3-heptanoyloxy-2,2-dimethylpropyl) heptanoate Chemical compound CCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCC NRTKYSGFUISGRQ-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- VQMHSKWEJGIXGA-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-6-dodecyl-4-methylphenol Chemical compound CCCCCCCCCCCCC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O VQMHSKWEJGIXGA-UHFFFAOYSA-N 0.000 description 2
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 2
- UADWUILHKRXHMM-UHFFFAOYSA-N 2-ethylhexyl benzoate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1 UADWUILHKRXHMM-UHFFFAOYSA-N 0.000 description 2
- FTLLYZOWBWEERE-UHFFFAOYSA-N 2-phenoxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCOC1=CC=CC=C1 FTLLYZOWBWEERE-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- AOPBNXIZCWMCPP-UHFFFAOYSA-N 3-[dimethoxy(phenyl)methoxy]-3-oxopropaneperoxoic acid Chemical compound OOC(=O)CC(=O)OC(OC)(OC)C1=CC=CC=C1 AOPBNXIZCWMCPP-UHFFFAOYSA-N 0.000 description 2
- XBBMJUWOCGWHRP-UHFFFAOYSA-N 3-octanoyloxypropyl octanoate Chemical compound CCCCCCCC(=O)OCCCOC(=O)CCCCCCC XBBMJUWOCGWHRP-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- PJTNSWOJMXNNFG-UHFFFAOYSA-N 8-methylnonyl 2-hydroxybenzoate Chemical compound CC(C)CCCCCCCOC(=O)C1=CC=CC=C1O PJTNSWOJMXNNFG-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- UMVMVEZHMZTUHD-UHFFFAOYSA-N DL-Propylene glycol dibenzoate Chemical compound C=1C=CC=CC=1C(=O)OC(C)COC(=O)C1=CC=CC=C1 UMVMVEZHMZTUHD-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- VIZORQUEIQEFRT-UHFFFAOYSA-N Diethyl adipate Chemical compound CCOC(=O)CCCCC(=O)OCC VIZORQUEIQEFRT-UHFFFAOYSA-N 0.000 description 2
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 2
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- UUGLJVMIFJNVFH-UHFFFAOYSA-N Hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1 UUGLJVMIFJNVFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 101800003332 Metamorphosin A Proteins 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- YOAHKNVSNCMZGQ-XPWFQUROSA-N P(1),P(4)-bis(5'-adenosyl) tetraphosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 YOAHKNVSNCMZGQ-XPWFQUROSA-N 0.000 description 2
- 241000206754 Palmaria palmata Species 0.000 description 2
- 244000037433 Pongamia pinnata Species 0.000 description 2
- 235000004599 Pongamia pinnata Nutrition 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 101710188106 SEC14-like protein 2 Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 241000219995 Wisteria Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002225 anti-radical effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229940067599 ascorbyl glucoside Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WMWLMWRWZQELOS-UHFFFAOYSA-N bismuth(III) oxide Inorganic materials O=[Bi]O[Bi]=O WMWLMWRWZQELOS-UHFFFAOYSA-N 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940080421 coco glucoside Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940067572 diethylhexyl adipate Drugs 0.000 description 2
- OLGWXCQXRSSQPO-UHFFFAOYSA-N diguanosine tetraphosphate Natural products C1=NC(C(N=C(N)N2)=O)=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OCC(C(O)C1O)OC1N1C=NC2=C1NC(N)=NC2=O OLGWXCQXRSSQPO-UHFFFAOYSA-N 0.000 description 2
- 229940031769 diisobutyl adipate Drugs 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 229940095130 dimethyl capramide Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 2
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229940115478 isopropyl lauroyl sarcosinate Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HNXNKTMIVROLTK-UHFFFAOYSA-N n,n-dimethyldecanamide Chemical compound CCCCCCCCCC(=O)N(C)C HNXNKTMIVROLTK-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical class OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940098888 phenethyl benzoate Drugs 0.000 description 2
- 230000003711 photoprotective effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- XLCIFRJORZNGEV-UHFFFAOYSA-N propan-2-yl 2-[dodecanoyl(methyl)amino]acetate Chemical compound CCCCCCCCCCCC(=O)N(C)CC(=O)OC(C)C XLCIFRJORZNGEV-UHFFFAOYSA-N 0.000 description 2
- 229940035652 propanediol dicaprylate Drugs 0.000 description 2
- 239000011814 protection agent Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003902 salicylic acid esters Chemical class 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000005555 sulfoximide group Chemical group 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VLMWBWYAHNRUGC-UHFFFAOYSA-N tridecyl 2-hydroxybenzoate Chemical compound CCCCCCCCCCCCCOC(=O)C1=CC=CC=C1O VLMWBWYAHNRUGC-UHFFFAOYSA-N 0.000 description 2
- PJHKBYALYHRYSK-UHFFFAOYSA-N triheptanoin Chemical compound CCCCCCC(=O)OCC(OC(=O)CCCCCC)COC(=O)CCCCCC PJHKBYALYHRYSK-UHFFFAOYSA-N 0.000 description 2
- 229940078561 triheptanoin Drugs 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IHWPQGIYXJKCOV-PTNGSMBKSA-N (z)-3-hydroxy-1-(4-methoxy-1-benzofuran-5-yl)-3-phenylprop-2-en-1-one Chemical compound C1=CC=2OC=CC=2C(OC)=C1C(=O)\C=C(/O)C1=CC=CC=C1 IHWPQGIYXJKCOV-PTNGSMBKSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- TXNWMICHNKMOBR-UHFFFAOYSA-N 1,2-dimethylcyclohexene Chemical compound CC1=C(C)CCCC1 TXNWMICHNKMOBR-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- PPVDHXWQWABSBC-UHFFFAOYSA-N 2-(2,6-diethyl-4-hydroxy-3,5-dimethoxyphenyl)-2-hexyl-1,3-dioxane-4,6-dione Chemical compound CCC=1C(OC)=C(O)C(OC)=C(CC)C=1C1(CCCCCC)OC(=O)CC(=O)O1 PPVDHXWQWABSBC-UHFFFAOYSA-N 0.000 description 1
- CZVOIAOPRGNENY-UHFFFAOYSA-N 2-butyloctyl 2-hydroxybenzoate Chemical compound CCCCCCC(CCCC)COC(=O)C1=CC=CC=C1O CZVOIAOPRGNENY-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- OCISOSJGBCQHHN-UHFFFAOYSA-N 3-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=CC(O)=CC2=C1 OCISOSJGBCQHHN-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- GWXXFGWOWOJEEX-UHFFFAOYSA-N 4,4,4-trihydroxy-1-phenylbutan-1-one Chemical compound OC(CCC(=O)C1=CC=CC=C1)(O)O GWXXFGWOWOJEEX-UHFFFAOYSA-N 0.000 description 1
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000746375 Andrographis Species 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 108091023231 Ap4A Proteins 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 241000893955 Blidingia minima Species 0.000 description 1
- OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 description 1
- 101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241001288418 Chironomus riparius Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LAAPRQODJPXAHC-UHFFFAOYSA-N Coniferyl benzoate Natural products C1=C(O)C(OC)=CC(C=CCOC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-UHFFFAOYSA-N 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- ZAVYLQGLQYIKKF-UHFFFAOYSA-N D-lyxo-hexos-5-ulose Natural products OCC(=O)C(O)C(O)C(O)C=O ZAVYLQGLQYIKKF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- 108010090549 Endothelin A Receptor Proteins 0.000 description 1
- 102100040630 Endothelin-1 receptor Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 235000016622 Filipendula ulmaria Nutrition 0.000 description 1
- 244000061544 Filipendula vulgaris Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100021792 Gamma-sarcoglycan Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 101000616435 Homo sapiens Gamma-sarcoglycan Proteins 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241000295519 Laminaria ochroleuca Species 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- OLGWXCQXRSSQPO-MHARETSRSA-N P(1),P(4)-bis(5'-guanosyl) tetraphosphate Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=C(NC2=O)N)=C2N=C1 OLGWXCQXRSSQPO-MHARETSRSA-N 0.000 description 1
- GVCMITUTKAQVPW-UHFFFAOYSA-N P1(OCCCCO1)=O.C(CN)N.[Na].[Na].[Na].[Na].[Na] Chemical compound P1(OCCCCO1)=O.C(CN)N.[Na].[Na].[Na].[Na].[Na] GVCMITUTKAQVPW-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000021273 Peumus boldus Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000565347 Pongamia Species 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- KJQFBVYMGADDTQ-UHFFFAOYSA-N S-butyl-DL-homocysteine (S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 1
- ARCJQKUWGAZPFX-KBPBESRZSA-N S-trans-stilbene oxide Chemical compound C1([C@H]2[C@@H](O2)C=2C=CC=CC=2)=CC=CC=C1 ARCJQKUWGAZPFX-KBPBESRZSA-N 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- CKZZREIPBTYJEQ-UHFFFAOYSA-N Totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(C)C=C2 CKZZREIPBTYJEQ-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 244000294617 Zanthoxylum alatum Species 0.000 description 1
- 235000004417 Zanthoxylum alatum Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- BGYHLZZASRKEJE-UHFFFAOYSA-N [3-[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxy]-2,2-bis[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxymethyl]propyl] 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CCC(=O)OCC(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 BGYHLZZASRKEJE-UHFFFAOYSA-N 0.000 description 1
- AJZRPMVVFWWBIW-UHFFFAOYSA-N [Au].[Bi] Chemical compound [Au].[Bi] AJZRPMVVFWWBIW-UHFFFAOYSA-N 0.000 description 1
- ARNJDXAPUCHUQL-UHFFFAOYSA-N [Ce].[Au] Chemical compound [Ce].[Au] ARNJDXAPUCHUQL-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940070313 arctostaphylos uva-ursi leaf extract Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 229940117895 bakuchiol Drugs 0.000 description 1
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 1
- VYTBDSUNRJYVHL-UHFFFAOYSA-N beta-Hydrojuglone Natural products O=C1CCC(=O)C2=C1C=CC=C2O VYTBDSUNRJYVHL-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- LAAPRQODJPXAHC-AATRIKPKSA-N coniferyl benzoate Chemical compound C1=C(O)C(OC)=CC(\C=C\COC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-AATRIKPKSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229960000355 copper sulfate Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- HKZLNGQCWGVZIW-UHFFFAOYSA-N cyclohex-2-en-1-imine Chemical compound N=C1CCCC=C1 HKZLNGQCWGVZIW-UHFFFAOYSA-N 0.000 description 1
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- JYIMWRSJCRRYNK-UHFFFAOYSA-N dialuminum;disodium;oxygen(2-);silicon(4+);hydrate Chemical compound O.[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Al+3].[Al+3].[Si+4] JYIMWRSJCRRYNK-UHFFFAOYSA-N 0.000 description 1
- 229940105984 diethylhexyl succinate Drugs 0.000 description 1
- 229940116365 diethylhexyl syringylidenemalonate Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000598 endocrine disruptor Substances 0.000 description 1
- 231100000049 endocrine disruptor Toxicity 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 231100000584 environmental toxicity Toxicity 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- UQPHVQVXLPRNCX-UHFFFAOYSA-N erythrulose Chemical compound OCC(O)C(=O)CO UQPHVQVXLPRNCX-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000003722 gum benzoin Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- JLPAWRLRMTZCSF-UHFFFAOYSA-N hydroxypyruvaldehyde Chemical compound OCC(=O)C=O JLPAWRLRMTZCSF-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920009537 polybutylene succinate adipate Polymers 0.000 description 1
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920005591 polysilicon Polymers 0.000 description 1
- IHWPQGIYXJKCOV-UHFFFAOYSA-N pongamol Natural products C1=CC=2OC=CC=2C(OC)=C1C(=O)C=C(O)C1=CC=CC=C1 IHWPQGIYXJKCOV-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- ARCJQKUWGAZPFX-UHFFFAOYSA-N stilbene oxide Chemical compound O1C(C=2C=CC=CC=2)C1C1=CC=CC=C1 ARCJQKUWGAZPFX-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ZRVDANDJSTYELM-FXAWDEMLSA-N totarol Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)C1=C2C(C(C)C)=C(O)C=C1 ZRVDANDJSTYELM-FXAWDEMLSA-N 0.000 description 1
- 229940074347 totarol Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- ZRVDANDJSTYELM-UHFFFAOYSA-N trans-totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(O)C=C2 ZRVDANDJSTYELM-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
- RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical class [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 1
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/411—Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4966—Triazines or their condensed derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention concerne une composition et son utilisation pour la protection contre le rayonnement solaire ultraviolet. En particulier, l'invention concerne une composition comprenant: - au moins un acide aminé analogue de la mycosporine dit « MAA »; - au moins deux filtres organiques choisis parmi les filtres organiques UVB et/ou les filtres organiques à large spectre absorbant à la fois dans les UVB et les UVA; - au moins un filtre organique UVA.
Description
ANTI-SUN COSMETIC COMPOSITION CONTAINING
MYCOSPORIN-LIKE AMINO ACIDS
Field of the invention The present invention relates to a composition, in particular a cosmetic or dennatological composition, advantageously solar, comprising mycosporin-like amino acids and solar screening agents, as well as its use to protect the skin against ultraviolet radiation.
Prior state of the art Ultraviolet (UV) radiation consists of light with a wavelength between 100 nm and 400 nm, traditionally divided into 3 subgroups: UVA (400-315 nm), UVB (315-280 nm) and UV-C (280-100 nm). UV-C, of short wavelength, is the most high-energy and harmful UV. It is screening agented by the ozone layer of the atmosphere and does flot reach the Earth's surface in considerable quantities.
Most skin damage is caused by UVA and UVB.
UVB induces production of the skin's natural pigment called "melanin", which is the origin of the phenomenon commonly called "tanning". UVB also stimulates cells to produce thicker epidermis. The reactions described above constitute a defense mechanism of the body against UV radiation.
The high energy of UVB generates molecular disorders (DNA alteration and protein damage) which, in the long term, saturate and block the nuclear DNA repair system. This leads to permanent mutations in the genome of affected cells, which are the cause of skin cancer. In this case, it is a direct UVB
toxicity. As for UVA, it is known that it penetrates the deeper layers of the skin, where it produces harmful effects, particularly within connective tissue and on blood vessels.
In particular, it is the cause of the phenomenon called "helioderma", i.e., the premature actinic aging of the skin.
In addition, although UVB is the main cause of skin cancer, UVA also contributes indirectly to this type of damage. Indeed, UVA and UVB are the cause of production of free radicals, in particular ROS
(Reactive Oxygen Species). These are very unstable molecules with a very short half-life, in the order of a nanosecond to a millisecond. ROS are capable of damaging intracellular structures (DNA, membranes, intracellular proteins, etc.) as well as extracellular structures (components of the
MYCOSPORIN-LIKE AMINO ACIDS
Field of the invention The present invention relates to a composition, in particular a cosmetic or dennatological composition, advantageously solar, comprising mycosporin-like amino acids and solar screening agents, as well as its use to protect the skin against ultraviolet radiation.
Prior state of the art Ultraviolet (UV) radiation consists of light with a wavelength between 100 nm and 400 nm, traditionally divided into 3 subgroups: UVA (400-315 nm), UVB (315-280 nm) and UV-C (280-100 nm). UV-C, of short wavelength, is the most high-energy and harmful UV. It is screening agented by the ozone layer of the atmosphere and does flot reach the Earth's surface in considerable quantities.
Most skin damage is caused by UVA and UVB.
UVB induces production of the skin's natural pigment called "melanin", which is the origin of the phenomenon commonly called "tanning". UVB also stimulates cells to produce thicker epidermis. The reactions described above constitute a defense mechanism of the body against UV radiation.
The high energy of UVB generates molecular disorders (DNA alteration and protein damage) which, in the long term, saturate and block the nuclear DNA repair system. This leads to permanent mutations in the genome of affected cells, which are the cause of skin cancer. In this case, it is a direct UVB
toxicity. As for UVA, it is known that it penetrates the deeper layers of the skin, where it produces harmful effects, particularly within connective tissue and on blood vessels.
In particular, it is the cause of the phenomenon called "helioderma", i.e., the premature actinic aging of the skin.
In addition, although UVB is the main cause of skin cancer, UVA also contributes indirectly to this type of damage. Indeed, UVA and UVB are the cause of production of free radicals, in particular ROS
(Reactive Oxygen Species). These are very unstable molecules with a very short half-life, in the order of a nanosecond to a millisecond. ROS are capable of damaging intracellular structures (DNA, membranes, intracellular proteins, etc.) as well as extracellular structures (components of the
2 extracellular matrix such as collagen fibers, etc.). ROS also exert an indirect harmful action, by causing the oxidation of membrane lipids, which induces the formation of reactive carbonyl species that contribute to amplifying tissue and cellular damage.
Therefore, it is necessary to combat the harmful effects of UV radiation, particularly UVA and UVB, taking into account interindividual differences such as skin type (phototype) and sun exposure times.
For this reason, anti-sun compositions have been developed to ensure photoprotection of areas subject to UV radiation. These compositions are in the form of lotion, oit, oit-in-water or water-in-oit type emulsion, foam, gel, stick or spray. They contain a cosmetically acceptable support and one or more chemical screening agents or minerai screens at various concentrations.
Mineral sunscreens, including zinc oxides and titanium dioxides, protect against UV rays by reflecting sunlight. Therefore, they act like mirrors located on the surface of the skin.
Minerai screens, at least in micrometric formulations, are safe for human use and pose no health risks.
However, they have disadvantages:
- minerai screens tend to dry out the skin and spread with difficulty, leaving white streaks on the skin that can be very unsightly;
- the galenic assessment minerai screen-based compositions is often poor, particularly in silicone-free compositions.
Chemical screening agents are organic compounds that absorb light, creating a screening agenting layer on the skin that neutralizes UV rays. Thus, when the solar screening agent molecule receives UV
radiation, it goes into an excited state by absorbing the energy of the radiation and then returns to its stable state. By this mechanism, light radiation is converted into heat and dissipated. Therefore, chemical screening agents act in the same way as melanin, the skin's natural photoprotective pigment.
Most chemical or organic screening agents are lipophilic and are, therefore, suitable for use in highly water-resistant compositions. From a galenic point of view, organic screening agent-based compositions are generally more appreciated than mineral screen-based compositions, thereby making it possible to improve compliance by users.
In Europe, all organic screening agents or mineral screens, authorized by regulations, are included in a list (Annex VI of the European Cosmetic Products Directive). This is a list currently containing
Therefore, it is necessary to combat the harmful effects of UV radiation, particularly UVA and UVB, taking into account interindividual differences such as skin type (phototype) and sun exposure times.
For this reason, anti-sun compositions have been developed to ensure photoprotection of areas subject to UV radiation. These compositions are in the form of lotion, oit, oit-in-water or water-in-oit type emulsion, foam, gel, stick or spray. They contain a cosmetically acceptable support and one or more chemical screening agents or minerai screens at various concentrations.
Mineral sunscreens, including zinc oxides and titanium dioxides, protect against UV rays by reflecting sunlight. Therefore, they act like mirrors located on the surface of the skin.
Minerai screens, at least in micrometric formulations, are safe for human use and pose no health risks.
However, they have disadvantages:
- minerai screens tend to dry out the skin and spread with difficulty, leaving white streaks on the skin that can be very unsightly;
- the galenic assessment minerai screen-based compositions is often poor, particularly in silicone-free compositions.
Chemical screening agents are organic compounds that absorb light, creating a screening agenting layer on the skin that neutralizes UV rays. Thus, when the solar screening agent molecule receives UV
radiation, it goes into an excited state by absorbing the energy of the radiation and then returns to its stable state. By this mechanism, light radiation is converted into heat and dissipated. Therefore, chemical screening agents act in the same way as melanin, the skin's natural photoprotective pigment.
Most chemical or organic screening agents are lipophilic and are, therefore, suitable for use in highly water-resistant compositions. From a galenic point of view, organic screening agent-based compositions are generally more appreciated than mineral screen-based compositions, thereby making it possible to improve compliance by users.
In Europe, all organic screening agents or mineral screens, authorized by regulations, are included in a list (Annex VI of the European Cosmetic Products Directive). This is a list currently containing
3 approximately thirty compounds according to their INCI designation which the cosmetics industry must draw from in order to formulate sun protection products. However, this list is not static and is constantly evolving based on the results of scientific research. Indeed, several studies have demonstrated that some of the organic screening agents on this list could cause risks to human health and the environment, particularly because they are suspected of acting as endocrine disruptors.
In particular, scientific results cast doubt on the safety of benzophenone-4 or even benzophenone-3 (Kinnberg et al. 2015; Zucchi et al. 2011), octyl methoxycinnamate (Szwarcfarb et al. 2008, Axelstad et al. 2011) 3-methylbenzylidene camphor and 4-methylbenzylidene camphor (Schlumpf et al. 2008;
Petersen et al. 2007), octocrylene, isoamyl methoxycinnamate, or else octyl dimethyl PABA
(Schlumpf et al. 2001; Rehfeld et al. 2016; Ozàez et al. 2016).
Alongside the possible effects on humans, the effect of these molecules on natural environments cannot be overlooked; indeed, the screening agents are continuously dispersed in bathing water or in wastewater. This water pollution, associated with UV screening agents, inevitably has repercussions throughout the food chain, with unpredictable consequences on the balance of an ecosystem already compromised by human activities; among other examples of ecotoxic effects, solar screening agents would have a negative impact on marine reefs and would be particularly responsible for the phenomenon of coral bleaching (Danovaro et al. 2008).
The graduai reduction in the number of organic solar screening agents, considered safe for human use and for the environment, increasingly complicates the formulation of cosmetic sunscreen products, particularly sunscreen products with a high protection factor, i.e., with an SPF ("Sun Protection Factor") greater than 20 or even 30. The formulation of a product with high sun protection is particularly difficult in the case of products made for the Canadian and American market, where only part of the latest generation screening agents used in Europe for two decades is authorized.
To compensate for the reduced number of usable solar screening agents, sun protection agents are often formulated in cosmetic products. These sun protection agents are sometimes molecules close to authorized solar screening agents, or plastic derivatives, which can, therefore, suffer fi-om the same disadvantages as organic solar screening agents; in particular, their ecotoxicity could be significant.
An interesting family of protective agents is represented by Mycosporin-like Amino Acids (or MAAs).
In particular, scientific results cast doubt on the safety of benzophenone-4 or even benzophenone-3 (Kinnberg et al. 2015; Zucchi et al. 2011), octyl methoxycinnamate (Szwarcfarb et al. 2008, Axelstad et al. 2011) 3-methylbenzylidene camphor and 4-methylbenzylidene camphor (Schlumpf et al. 2008;
Petersen et al. 2007), octocrylene, isoamyl methoxycinnamate, or else octyl dimethyl PABA
(Schlumpf et al. 2001; Rehfeld et al. 2016; Ozàez et al. 2016).
Alongside the possible effects on humans, the effect of these molecules on natural environments cannot be overlooked; indeed, the screening agents are continuously dispersed in bathing water or in wastewater. This water pollution, associated with UV screening agents, inevitably has repercussions throughout the food chain, with unpredictable consequences on the balance of an ecosystem already compromised by human activities; among other examples of ecotoxic effects, solar screening agents would have a negative impact on marine reefs and would be particularly responsible for the phenomenon of coral bleaching (Danovaro et al. 2008).
The graduai reduction in the number of organic solar screening agents, considered safe for human use and for the environment, increasingly complicates the formulation of cosmetic sunscreen products, particularly sunscreen products with a high protection factor, i.e., with an SPF ("Sun Protection Factor") greater than 20 or even 30. The formulation of a product with high sun protection is particularly difficult in the case of products made for the Canadian and American market, where only part of the latest generation screening agents used in Europe for two decades is authorized.
To compensate for the reduced number of usable solar screening agents, sun protection agents are often formulated in cosmetic products. These sun protection agents are sometimes molecules close to authorized solar screening agents, or plastic derivatives, which can, therefore, suffer fi-om the same disadvantages as organic solar screening agents; in particular, their ecotoxicity could be significant.
An interesting family of protective agents is represented by Mycosporin-like Amino Acids (or MAAs).
4 MAAs are small heterocyclic molecules (<400 Da) comprising cyclohexenone or cyclohexenimine chromophores.
MAAs are found naturally as secondary metabolites in marine organisms, such as corals, algae and cyanobacteria, and are, therefore, expected to be eco-compatible and respectful of aquatic ecosystems.
In particular, document EP2855441 discloses a family of compounds, of the MAA
type, having the following general JE formula:
Ré Y R5 * 118 bis, . NH
Ill That document specifies that these compounds, fi-om the TE molecule family, absorb ultraviolet radiation and may be used as an anti-UV agent. The compounds of formulas IA1 and 1E4 having a sun protection factor of 2.4 and 4.5, respectively, are given as examples.
Thus, although the MAAs of the TE molecule family absorb UV radiation, their sun protection factor is insufficient for use in anti-sun cosmetic compositions.
Although considered good candidates for the formulation of eco-compatible solar products, a solution must be found to improve the anti-UV potential of MAAs, in order to be able to use them in solar products.
Thus, the present invention aims to overcome the disadvantages of the state of the art, by proposing an ecobiological composition comprising MMAs and whose SPF is compatible with topical solar application.
Disclosure of the invention The applicant observed, quite surprisingly, that combining MMAs with at least two organic UVBs
MAAs are found naturally as secondary metabolites in marine organisms, such as corals, algae and cyanobacteria, and are, therefore, expected to be eco-compatible and respectful of aquatic ecosystems.
In particular, document EP2855441 discloses a family of compounds, of the MAA
type, having the following general JE formula:
Ré Y R5 * 118 bis, . NH
Ill That document specifies that these compounds, fi-om the TE molecule family, absorb ultraviolet radiation and may be used as an anti-UV agent. The compounds of formulas IA1 and 1E4 having a sun protection factor of 2.4 and 4.5, respectively, are given as examples.
Thus, although the MAAs of the TE molecule family absorb UV radiation, their sun protection factor is insufficient for use in anti-sun cosmetic compositions.
Although considered good candidates for the formulation of eco-compatible solar products, a solution must be found to improve the anti-UV potential of MAAs, in order to be able to use them in solar products.
Thus, the present invention aims to overcome the disadvantages of the state of the art, by proposing an ecobiological composition comprising MMAs and whose SPF is compatible with topical solar application.
Disclosure of the invention The applicant observed, quite surprisingly, that combining MMAs with at least two organic UVBs
5 and/or broad-spectrum screening agents in the presence of at least one organic UVA screening agent made it possible to obtain an SPF with a value greater than that of the sum of the respective SPFs of the MAAs and organic screening agents.
Therefore, this combination lends itself to their implementation in compositions with high solar protection with relatively low levels of organic screening agents.
Thus, according to a first aspect, the invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:
¨ at least one amino acid analog of mycosporin called "MAA";
¨ at least two organic UVB screening agents and/or at least two broad-spectrum organic screening agents;
¨ at least one organic UVA screening agent.
According to another aspect, the invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:
¨ at least one amino acid analog of mycosporin called "MAA" chosen from the group consisting of molecules A of formula IA or one of its acceptable salts, and/or the group consisting of molecules B of formula IB or one of its acceptable salts, said formula IA being:
Formula IA:
10 Ri Formula IB:
Therefore, this combination lends itself to their implementation in compositions with high solar protection with relatively low levels of organic screening agents.
Thus, according to a first aspect, the invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:
¨ at least one amino acid analog of mycosporin called "MAA";
¨ at least two organic UVB screening agents and/or at least two broad-spectrum organic screening agents;
¨ at least one organic UVA screening agent.
According to another aspect, the invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:
¨ at least one amino acid analog of mycosporin called "MAA" chosen from the group consisting of molecules A of formula IA or one of its acceptable salts, and/or the group consisting of molecules B of formula IB or one of its acceptable salts, said formula IA being:
Formula IA:
10 Ri Formula IB:
6 eS
N N
Ri wherein:
R1 is hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl;
alkoxy; alkanoyl; hydroxyl; a sulfo group; a halogen group; a phosphono group; an ester group; a carboxylic acid group; a phenyl group; an amino group; an alkylated fatty acid chain or a polyether;
R2 is alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl; alkoxy;
alkanoyl; a sulfo group; a phosphono group; an ester group; a carboxylic acid group; hydroxyl; or a phenyl group;
said composition further comprising:
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both UVBs and UVAs;
¨ at least one organic UVA screening agent.
According to a particular embodiment, the composition according to the invention is ecobiological.
The term "ecobiological composition" is understood to mean respectful of the person, their interactions with the world, and the planet.
The MAAs according to the invention are known to a person skilled in the art and disclosed, for example, in patent application W02013/181741 which details the process for obtaining and purifying them.
According to a particular embodiment, R1 is an alkoxy group of the [CH3]-[CH211-0- type, wherein "n" is between 0 and 10. According to a preferred embodiment, "n"=0 or "n"=8.
According to a particular embodiment of the invention, R2 is a carboxylic acid group of the type [COOH]-[CH211-, wherein "n" is between 0 and 5, or preferably "n"=1 or "n"=0.
N N
Ri wherein:
R1 is hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl;
alkoxy; alkanoyl; hydroxyl; a sulfo group; a halogen group; a phosphono group; an ester group; a carboxylic acid group; a phenyl group; an amino group; an alkylated fatty acid chain or a polyether;
R2 is alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl; alkoxy;
alkanoyl; a sulfo group; a phosphono group; an ester group; a carboxylic acid group; hydroxyl; or a phenyl group;
said composition further comprising:
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both UVBs and UVAs;
¨ at least one organic UVA screening agent.
According to a particular embodiment, the composition according to the invention is ecobiological.
The term "ecobiological composition" is understood to mean respectful of the person, their interactions with the world, and the planet.
The MAAs according to the invention are known to a person skilled in the art and disclosed, for example, in patent application W02013/181741 which details the process for obtaining and purifying them.
According to a particular embodiment, R1 is an alkoxy group of the [CH3]-[CH211-0- type, wherein "n" is between 0 and 10. According to a preferred embodiment, "n"=0 or "n"=8.
According to a particular embodiment of the invention, R2 is a carboxylic acid group of the type [COOH]-[CH211-, wherein "n" is between 0 and 5, or preferably "n"=1 or "n"=0.
7 According to an alternative embodiment of the invention, R2 is an ester group of the type [CF13]-[CH2],-[COOH] -, wherein "n" is between 0 and 5, or preferably "n"= 1 or "n"=2.
According to another particular embodiment, R1 is an alkoxy group of the [CH3]-[CH2].-0- type, where "n"=0; R2 is an ester group of the type [CH3]-[CF12].-[COOI-1] -, where "n"=1 or "n"=2 or R2 is a carboxylic acid group of the type [COOFI]-[CI-12], -, wherein "n" is between 0 and 5, or preferably "n"=1 or Thus, and according to a particular embodiment, the MAA according to formula IA corresponds to the molecule of formula IIA1 below:
Formula IIAl:
o I
e 0/
This molecule of formula IIA1 : [N- [(3E)-3- [(4-methoxyphenyl)imino] -5 ,5-dimethyl- 1-cyclohexen-1 -yll-glycine, corresponding to CAS number 1509902-01- 5] is marketed by ELKIMIA
Inc. under the INCI designation: methoxyphenylimino dimethylcyclohexene glycine.
In another embodiment, the MAA according to formula IA corresponds to the molecule of formula IIA2 bel ow:
According to another particular embodiment, R1 is an alkoxy group of the [CH3]-[CH2].-0- type, where "n"=0; R2 is an ester group of the type [CH3]-[CF12].-[COOI-1] -, where "n"=1 or "n"=2 or R2 is a carboxylic acid group of the type [COOFI]-[CI-12], -, wherein "n" is between 0 and 5, or preferably "n"=1 or Thus, and according to a particular embodiment, the MAA according to formula IA corresponds to the molecule of formula IIA1 below:
Formula IIAl:
o I
e 0/
This molecule of formula IIA1 : [N- [(3E)-3- [(4-methoxyphenyl)imino] -5 ,5-dimethyl- 1-cyclohexen-1 -yll-glycine, corresponding to CAS number 1509902-01- 5] is marketed by ELKIMIA
Inc. under the INCI designation: methoxyphenylimino dimethylcyclohexene glycine.
In another embodiment, the MAA according to formula IA corresponds to the molecule of formula IIA2 bel ow:
8 Formula IIA2:
NI N
This molecule of formula IIA2: [N-[3-[(4-methoxyphenyl)amino]-5,5-dimethy1-2-cyclohexen-1-ylidene]-, ethyl ester, [N(E)]-glycine, corresponding to CAS number 2640340-86-7] is available fi-om SENSIENT Inc. under the trade name SENSISORBTm BIOMIM (INCE methoxyphenylimino dimethylcyclohexenyl ethyl glycinate).
According to a preferred embodiment, the MAA according to formula IB
corresponds to the molecule of formula IIB1 below:
Formula IIB1 o 0.).S
N N
)10 I...
`===,..,
NI N
This molecule of formula IIA2: [N-[3-[(4-methoxyphenyl)amino]-5,5-dimethy1-2-cyclohexen-1-ylidene]-, ethyl ester, [N(E)]-glycine, corresponding to CAS number 2640340-86-7] is available fi-om SENSIENT Inc. under the trade name SENSISORBTm BIOMIM (INCE methoxyphenylimino dimethylcyclohexenyl ethyl glycinate).
According to a preferred embodiment, the MAA according to formula IB
corresponds to the molecule of formula IIB1 below:
Formula IIB1 o 0.).S
N N
)10 I...
`===,..,
9 This molecule of formula IIB1 [3,5,6,7-tetrahydro-6,6-dimethy1-84[4-(octyloxy)phenyl]amino]-211-1,4-Benzothiazine-3-carboxylic acid, corresponding to CAS number 1629023-01-3]
is marketed by ELKIMIA Inc. under the INCI designation: caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid.
According to an alternative embodiment, the MAA according to formula IB
corresponds to the molecule of formula IIB2 below:
Formula IIB2 o 0 s NO N
This molecule of formula IIB2 [3,5,6,7-tetrahydro-8-[(4-methoxyphenyl)amino]-6,6-dimethy1-211-1,4-Benzothiazine-3-carboxylic acid corresponding to CAS number 1629023 -04-6]
is marketed by ELKIMIA Inc. under the INCI designation: methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid.
According to an alternative embodiment, the MAA according to formula IB
corresponds to the molecule of formula IIB3 below.
is marketed by ELKIMIA Inc. under the INCI designation: caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid.
According to an alternative embodiment, the MAA according to formula IB
corresponds to the molecule of formula IIB2 below:
Formula IIB2 o 0 s NO N
This molecule of formula IIB2 [3,5,6,7-tetrahydro-8-[(4-methoxyphenyl)amino]-6,6-dimethy1-211-1,4-Benzothiazine-3-carboxylic acid corresponding to CAS number 1629023 -04-6]
is marketed by ELKIMIA Inc. under the INCI designation: methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid.
According to an alternative embodiment, the MAA according to formula IB
corresponds to the molecule of formula IIB3 below.
10 Formula IIB3:
N
S
N
This molecule of formula ethylester-(3R)-2H-1,4-Benzothiazine-3-carboxylic acid, 3,4,5,6,7,8-hexahydro-8-[(4-methoxyphenypimino]-6,6-dimethyl corresponds to CAS number 2699128-33-9.
In a particular embodiment of the invention, the compositions according to the invention contain at least two MAAs as defined above, in particular chosen from the molecules corresponding to the INCI
designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid and methoxyphenylimino dimethylcyclohexenyl ethyl glycinate as well as, optionally, the compound corresponding to CAS number 2699128-33-9.
According to a particular embodiment, the compositions according to the invention contain at least three MAAs.
Within the meaning of the invention, the term "acceptable salts" is understood to mean any pharmacologically or cosmetically acceptable sait of MAA, such as, for exampleõ sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, isonicotinate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, pamoate and 3-hydroxynaphthoate salts.
According to a particular embodiment, the MAA(s) represent(s) between 0.1% and 20% by mass
N
S
N
This molecule of formula ethylester-(3R)-2H-1,4-Benzothiazine-3-carboxylic acid, 3,4,5,6,7,8-hexahydro-8-[(4-methoxyphenypimino]-6,6-dimethyl corresponds to CAS number 2699128-33-9.
In a particular embodiment of the invention, the compositions according to the invention contain at least two MAAs as defined above, in particular chosen from the molecules corresponding to the INCI
designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid and methoxyphenylimino dimethylcyclohexenyl ethyl glycinate as well as, optionally, the compound corresponding to CAS number 2699128-33-9.
According to a particular embodiment, the compositions according to the invention contain at least three MAAs.
Within the meaning of the invention, the term "acceptable salts" is understood to mean any pharmacologically or cosmetically acceptable sait of MAA, such as, for exampleõ sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, isonicotinate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, pamoate and 3-hydroxynaphthoate salts.
According to a particular embodiment, the MAA(s) represent(s) between 0.1% and 20% by mass
11 relative to the total mass of the composition, preferably between 0.5% and 10%, even more advantageously between 1 and 2%.
The term "organic solar screening agent" designates organic UVB screening agents, organic UVA
screening agents and broad-spectrum organic screening agents.
Within the meaning of the invention, the term "organic UVB screening agent" is understood to mean any organic solar screening agent, whether hydrophilic or lipophilic, which, mainly or exclusively, absorbs UVBs.
According to a particular embodiment, the organic UVB screening agent is chosen from salicylates.
More particularly, the organic UVB screening agent is chosen from the compounds corresponding to the following INCI designations: ethylhexyl salicylate and homosalate or else phenylbenzimidazole sulfonic acid or ethylhexyl triazone.
A source of the latter is the raw material UV1NULTM T150 marketed by BASF.
The organic UVB screening agent corresponding to the INCI designation:
phenylbenzimidazole sulfonic acid, for its part, is available from AAKO BV under the name AakoSun PBSA. Salicylates corresponding to the INCI designations: octyl salicylate and homosalate are available from SYMRISE
under the names Neo HeliopanTM OS and Neo HeliopanTM HMS, respectively.
According to a particular embodiment of the invention, said at least one organic UVB screening agent represents between 1% and 20% by mass relative to the total mass of the composition, preferably between 2% and 15%.
Within the meaning of the invention, the term "organic UVA screening agent" is understood to mean any organic solar screening agent, whether hydrophilic or lipophilic, which, mainly or exclusively, absorbs UVAs.
According to a preferred embodiment, the composition according to the invention comprises at least one UVA solar screening agent chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl
The term "organic solar screening agent" designates organic UVB screening agents, organic UVA
screening agents and broad-spectrum organic screening agents.
Within the meaning of the invention, the term "organic UVB screening agent" is understood to mean any organic solar screening agent, whether hydrophilic or lipophilic, which, mainly or exclusively, absorbs UVBs.
According to a particular embodiment, the organic UVB screening agent is chosen from salicylates.
More particularly, the organic UVB screening agent is chosen from the compounds corresponding to the following INCI designations: ethylhexyl salicylate and homosalate or else phenylbenzimidazole sulfonic acid or ethylhexyl triazone.
A source of the latter is the raw material UV1NULTM T150 marketed by BASF.
The organic UVB screening agent corresponding to the INCI designation:
phenylbenzimidazole sulfonic acid, for its part, is available from AAKO BV under the name AakoSun PBSA. Salicylates corresponding to the INCI designations: octyl salicylate and homosalate are available from SYMRISE
under the names Neo HeliopanTM OS and Neo HeliopanTM HMS, respectively.
According to a particular embodiment of the invention, said at least one organic UVB screening agent represents between 1% and 20% by mass relative to the total mass of the composition, preferably between 2% and 15%.
Within the meaning of the invention, the term "organic UVA screening agent" is understood to mean any organic solar screening agent, whether hydrophilic or lipophilic, which, mainly or exclusively, absorbs UVAs.
According to a preferred embodiment, the composition according to the invention comprises at least one UVA solar screening agent chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl
12 hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, especially butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.
For example, the UVA screening agents according to the invention correspond to the raw material Parsol 1789 (INCE butyl methoxydibenzoylmethane) marketed by DSM; the raw material UVINULTM A+ (INCE diethylamino hydroxybenzoyl hexyl benzoate) marketed by BASF; the raw material C1332TM [INCI: bis-(diethylaminohydroxybenzoyl benzoyl) piperazine;
CAS number 919803-06-8] marketed by BASF; or the raw material Neo HeliopanTM AP
corresponding to the INCI
designation: disodium phenyl dibenzimidazole tetrasulfonate, and marketed by SYMRISE.
According to a particular embodiment, said at least one organic UVA screening agent represents between 1% and 10% by mass relative to the total mass of the composition, preferably between 2%
and 7%.
Within the meaning of the invention, the term "broad-spectrum organic screening agent" is understood to mean any organic solar screening agent, whether hydrophilic or lipophilic, which absorbs both UVBs and UVAs. According to a preferred embodiment, the composition according to the invention comprises at least one broad-spectrum solar screening agent chosen fi-om the group comprising the compounds corresponding to the following INCI designations: bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, phenylene bis-diphenyltriazine, methylene bis-benzotriazolyl tetramethylbutylphenol and drometrizole trisiloxane, in particular bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, methylene bis-benzotriazolyl tetramethylbutylphenol.
These solar screening agents are available from the following suppliers:
¨ PARSOLTM Shield marketed by SYMRISE and corresponding to the INCI
designation: bis ethylhexyloxyphenol methoxyphenyl triazine;
¨ UVASORBTM HEB marketed by SIGMA 3V and corresponding to the INCI
designation:
diethylhexyl butamido triazone;
¨ TINOSORBTm A2B marketed by BASF and corresponding to the INCI
designation: tris-biphenyl triazine;
¨ TRIASORBTm marketed by PLANTES & INDUSTRIE and corresponding to the INCI
For example, the UVA screening agents according to the invention correspond to the raw material Parsol 1789 (INCE butyl methoxydibenzoylmethane) marketed by DSM; the raw material UVINULTM A+ (INCE diethylamino hydroxybenzoyl hexyl benzoate) marketed by BASF; the raw material C1332TM [INCI: bis-(diethylaminohydroxybenzoyl benzoyl) piperazine;
CAS number 919803-06-8] marketed by BASF; or the raw material Neo HeliopanTM AP
corresponding to the INCI
designation: disodium phenyl dibenzimidazole tetrasulfonate, and marketed by SYMRISE.
According to a particular embodiment, said at least one organic UVA screening agent represents between 1% and 10% by mass relative to the total mass of the composition, preferably between 2%
and 7%.
Within the meaning of the invention, the term "broad-spectrum organic screening agent" is understood to mean any organic solar screening agent, whether hydrophilic or lipophilic, which absorbs both UVBs and UVAs. According to a preferred embodiment, the composition according to the invention comprises at least one broad-spectrum solar screening agent chosen fi-om the group comprising the compounds corresponding to the following INCI designations: bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, phenylene bis-diphenyltriazine, methylene bis-benzotriazolyl tetramethylbutylphenol and drometrizole trisiloxane, in particular bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, methylene bis-benzotriazolyl tetramethylbutylphenol.
These solar screening agents are available from the following suppliers:
¨ PARSOLTM Shield marketed by SYMRISE and corresponding to the INCI
designation: bis ethylhexyloxyphenol methoxyphenyl triazine;
¨ UVASORBTM HEB marketed by SIGMA 3V and corresponding to the INCI
designation:
diethylhexyl butamido triazone;
¨ TINOSORBTm A2B marketed by BASF and corresponding to the INCI
designation: tris-biphenyl triazine;
¨ TRIASORBTm marketed by PLANTES & INDUSTRIE and corresponding to the INCI
13 designation: phenylene bis-diphenyltriazine (CAS number 55514-22-2);
¨ MEXORYLTM XL, corresponding to the INCI designation: drometrizole trisiloxane;
¨ TINOSORBTm M marketed by BASF and corresponding to the INCI designation:
methylene bis-benzotriazolyl tetramethylbutylphenol.
According to a particular embodiment, said at least one broad-spectrum organic screening agent represents between 1% and 15% by mass relative to the total mass of the composition, preferably between 2% and 10%.
According to a particular embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9, ¨ at least two organic UVB screening agents;
¨ at least one organic UVA screening agent.
According to an alternative embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two broad-spectrum organic screening agents;
¨ at least one organic UVA screening agent.
According to an alternative embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine
¨ MEXORYLTM XL, corresponding to the INCI designation: drometrizole trisiloxane;
¨ TINOSORBTm M marketed by BASF and corresponding to the INCI designation:
methylene bis-benzotriazolyl tetramethylbutylphenol.
According to a particular embodiment, said at least one broad-spectrum organic screening agent represents between 1% and 15% by mass relative to the total mass of the composition, preferably between 2% and 10%.
According to a particular embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9, ¨ at least two organic UVB screening agents;
¨ at least one organic UVA screening agent.
According to an alternative embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two broad-spectrum organic screening agents;
¨ at least one organic UVA screening agent.
According to an alternative embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine
14 carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least one organic UVB screening agent;
¨ at least one broad-spectrum organic screening agent;
¨ at least one organic UVA screening agent.
According to yet another embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least one organic UVB screening agent;
¨ at least two broad-spectrum organic screening agents;
¨ at least one organic UVA screening agent.
According to yet another embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two organic UVB screening agents;
¨ at least one broad-spectrum organic screening agent;
¨ at least one organic UVA screening agent.
According to another aspect, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino
¨ at least one organic UVB screening agent;
¨ at least one broad-spectrum organic screening agent;
¨ at least one organic UVA screening agent.
According to yet another embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least one organic UVB screening agent;
¨ at least two broad-spectrum organic screening agents;
¨ at least one organic UVA screening agent.
According to yet another embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two organic UVB screening agents;
¨ at least one broad-spectrum organic screening agent;
¨ at least one organic UVA screening agent.
According to another aspect, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino
15 dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least 2 UVB screening agents corresponding to the following INCI
designations: octyl salicylate and homosalate;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
butyl methoxydibenzoylmethane.
According to another embodiment, the composition according to the invention comprises as MAA and organic solar screening agents:
¨ one MAA chosen from the group consisting of the molecules corresponding to the INCI
designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine;
¨ 2 UVB screening agents corresponding to the following INCI designations:
octyl salicylate and homosalate;
¨ an organic UVA screening agent corresponding to the following INCI
designation: butyl methoxydibenzoylmethane.
According to another embodiment, the composition according to the invention comprises as MAAs and organic solar screening agents:
¨ two MAAs chosen from the group consisting of molecules corresponding to the INCI
designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine and methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid and methoxyphenylimino dimethylcyclohexenyl ethyl glycinate;
¨ 2 UVB screening agents corresponding to the following INCI designations:
octyl salicylate
¨ at least 2 UVB screening agents corresponding to the following INCI
designations: octyl salicylate and homosalate;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
butyl methoxydibenzoylmethane.
According to another embodiment, the composition according to the invention comprises as MAA and organic solar screening agents:
¨ one MAA chosen from the group consisting of the molecules corresponding to the INCI
designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine;
¨ 2 UVB screening agents corresponding to the following INCI designations:
octyl salicylate and homosalate;
¨ an organic UVA screening agent corresponding to the following INCI
designation: butyl methoxydibenzoylmethane.
According to another embodiment, the composition according to the invention comprises as MAAs and organic solar screening agents:
¨ two MAAs chosen from the group consisting of molecules corresponding to the INCI
designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine and methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid and methoxyphenylimino dimethylcyclohexenyl ethyl glycinate;
¨ 2 UVB screening agents corresponding to the following INCI designations:
octyl salicylate
16 and homosalate;
¨ an organic UVA screening agent corresponding to the following INCI
designation: butyl methoxydibenzoylmethane.
According to a particular embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least 2 UVB screening agents, corresponding to the following INCI
designations: octyl salicylate and homosalate;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
diethylamino hydroxybenzoyl hexyl benzoate.
According to a different embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two broad-spectrum screening agents corresponding to the following INCI
designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least one UVA solar screening agent chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, in particular butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate, advantageously butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.
¨ an organic UVA screening agent corresponding to the following INCI
designation: butyl methoxydibenzoylmethane.
According to a particular embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least 2 UVB screening agents, corresponding to the following INCI
designations: octyl salicylate and homosalate;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
diethylamino hydroxybenzoyl hexyl benzoate.
According to a different embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two broad-spectrum screening agents corresponding to the following INCI
designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least one UVA solar screening agent chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, in particular butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate, advantageously butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.
17 According to a different embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two broad-spectrum screening agents corresponding to the following INCI
designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least one UVA solar screening agent corresponding to the following INCI designation:
diethylamino hydroxybenzoyl hexyl benzoate.
According to another embodiment, the composition according to the invention comprises as MAA and organic solar screening agents:
¨ one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the corresponding compound with CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine;
¨ two broad-spectrum screening agents corresponding to the following INCI
designations:
diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ a UVA solar screening agent corresponding to the following INCI designation:
diethylamino hydroxybenzoyl hexyl benzoate.
According to an alternative embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the corresponding molecules corresponding to the INCI designations:
methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two broad-spectrum screening agents corresponding to the following INCI
designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least one UVA solar screening agent corresponding to the following INCI designation:
diethylamino hydroxybenzoyl hexyl benzoate.
According to another embodiment, the composition according to the invention comprises as MAA and organic solar screening agents:
¨ one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the corresponding compound with CAS number 2699128-33-9, advantageously methoxyphenylimino dimethylcyclohexene glycine;
¨ two broad-spectrum screening agents corresponding to the following INCI
designations:
diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ a UVA solar screening agent corresponding to the following INCI designation:
diethylamino hydroxybenzoyl hexyl benzoate.
According to an alternative embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the corresponding molecules corresponding to the INCI designations:
methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the
18 compound corresponding to CAS number 2699128-33-9;
¨ at least broad-spectrum screening agents corresponding to the following INCI designations:
diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least the organic UVB screening agent corresponding to the following INCI designation:
ethylhexyl triazone;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
butyl methoxydibenzoylmethane.
According to a particular embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the corresponding molecules corresponding to the INCI designations:
methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least broad-spectrum organic screening agents corresponding to the following INCI
designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least the organic UVB screening agent corresponding to the following INCI designation:
ethylhexyl triazone;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
diethylamino hydroxybenzoyl hexyl benzoate.
According to a particular embodiment, the composition according to the invention is free fi-om at least one, alternatively several solar screening agents corresponding to the following INCI designations: 4-methylbenzylidene camphor, 3-methylbenzylidene camphor, benzophenone-2, benzophenone-3, benzophenone -4, ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, octocrylene, octyl dimethyl PABA.
Preferably, the composition also includes at least one solar screening agent solubilizer. For the purposes of the invention, the term "solubilizer" is understood to mean a compound which makes it possible to solubilize, disperse and/or dissolve at least one solar screening agent derived from triazine in an effective and sustainable manner, i.e., by stabilizing it in its solubilized form while preventing
¨ at least broad-spectrum screening agents corresponding to the following INCI designations:
diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least the organic UVB screening agent corresponding to the following INCI designation:
ethylhexyl triazone;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
butyl methoxydibenzoylmethane.
According to a particular embodiment, the composition according to the invention comprises:
¨ at least one MAA as defined above, in particular chosen fi-om the group consisting of the corresponding molecules corresponding to the INCI designations:
methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least broad-spectrum organic screening agents corresponding to the following INCI
designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least the organic UVB screening agent corresponding to the following INCI designation:
ethylhexyl triazone;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
diethylamino hydroxybenzoyl hexyl benzoate.
According to a particular embodiment, the composition according to the invention is free fi-om at least one, alternatively several solar screening agents corresponding to the following INCI designations: 4-methylbenzylidene camphor, 3-methylbenzylidene camphor, benzophenone-2, benzophenone-3, benzophenone -4, ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, octocrylene, octyl dimethyl PABA.
Preferably, the composition also includes at least one solar screening agent solubilizer. For the purposes of the invention, the term "solubilizer" is understood to mean a compound which makes it possible to solubilize, disperse and/or dissolve at least one solar screening agent derived from triazine in an effective and sustainable manner, i.e., by stabilizing it in its solubilized form while preventing
19 or reducing its recrystallization or precipitation in formulation throughout the duration of use of the product.
Thus, the compositions according to the invention further comprise of least one solubilizer chosen from the group comprising the compounds corresponding to the following INCI
designations: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco-caprylate , C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate, dipropylene glycol dibenzoate, neopentyl glycol diheptanoate, triheptanoin, C12-13 alkyl lactate, ethylhexyl benzoate, Cl 2-C15 alkyl lactate, C12-13 alkyl tartrate, tridecyl salicylate, lauryl lactate, diethyl adipate, diisobutyl adipate, diisopropyl adipate, diethylhexyl adipate, diethylhexyl succinate, propanediol dicaprylate, propylene glycol dicaprylate/dicaprate, isopropyl lauroyl sarcosinate, propylene glycol dibenzoate, hydroxyl dimethoxybenzyl malonate, phenoxyethyl caprylate, isodecyl salicylate, dimethyl capramide and phenethyl benzoate, in particular at least two solubilizers chosen from the following group: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco-caprylate, C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate.
Solubilizers capable of being used in a composition according to the invention are available on the market from several suppliers. By way of example, the following raw materials may be used in the composition according to the invention:
¨ Several raw materials from the CETIOLTm range marketed by BASF, in particular CETIOLTm RLF, CETIOLTm B, CETIOLTm CC, CETIOLTm 0, CETIOLTm C5, CETIOLTm AB, CETIOLTm SENSOFT corresponding respectively to the following INCI
designations:
caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, dicaprylyl ether, coco-caprylate, C12-15 alkyl benzoate, propylheptyl caprylate;
¨ DUBTm DIS, DEA, DIBA, ZENOAT marketed by STEARINE DUBOIS corresponding respectively to the following INCI designations: diisopropyl sebacate, diethyl adipate, diisobutyl adipate and propanediol dicaprylate;
¨ MIGLYOLTM 8810 and MIGLYOLTM T-C7 marketed by TOI Oleo GmbH corresponding respectively to the following INCI designations: butylene glycol dicaprylate/dicaprate and triheptanoin;
¨ LexsolvTM A marketed by INOLEX corresponding to the following INCI
designations:
dipropylene glycol dibenzoate and neopentyl glycol diheptanoate;
Thus, the compositions according to the invention further comprise of least one solubilizer chosen from the group comprising the compounds corresponding to the following INCI
designations: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco-caprylate , C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate, dipropylene glycol dibenzoate, neopentyl glycol diheptanoate, triheptanoin, C12-13 alkyl lactate, ethylhexyl benzoate, Cl 2-C15 alkyl lactate, C12-13 alkyl tartrate, tridecyl salicylate, lauryl lactate, diethyl adipate, diisobutyl adipate, diisopropyl adipate, diethylhexyl adipate, diethylhexyl succinate, propanediol dicaprylate, propylene glycol dicaprylate/dicaprate, isopropyl lauroyl sarcosinate, propylene glycol dibenzoate, hydroxyl dimethoxybenzyl malonate, phenoxyethyl caprylate, isodecyl salicylate, dimethyl capramide and phenethyl benzoate, in particular at least two solubilizers chosen from the following group: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco-caprylate, C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate.
Solubilizers capable of being used in a composition according to the invention are available on the market from several suppliers. By way of example, the following raw materials may be used in the composition according to the invention:
¨ Several raw materials from the CETIOLTm range marketed by BASF, in particular CETIOLTm RLF, CETIOLTm B, CETIOLTm CC, CETIOLTm 0, CETIOLTm C5, CETIOLTm AB, CETIOLTm SENSOFT corresponding respectively to the following INCI
designations:
caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, dicaprylyl ether, coco-caprylate, C12-15 alkyl benzoate, propylheptyl caprylate;
¨ DUBTm DIS, DEA, DIBA, ZENOAT marketed by STEARINE DUBOIS corresponding respectively to the following INCI designations: diisopropyl sebacate, diethyl adipate, diisobutyl adipate and propanediol dicaprylate;
¨ MIGLYOLTM 8810 and MIGLYOLTM T-C7 marketed by TOI Oleo GmbH corresponding respectively to the following INCI designations: butylene glycol dicaprylate/dicaprate and triheptanoin;
¨ LexsolvTM A marketed by INOLEX corresponding to the following INCI
designations:
dipropylene glycol dibenzoate and neopentyl glycol diheptanoate;
20 ¨ COSMACOLTm EU, ET!, ES! and LL marketed by SASOL and corresponding respectively to the following INCI designations: C12-13 alkyl lactate, C12-13 alkyl tartrate, tridecyl salicylate and lauryl lactate;
¨ CeraphylTM 41 ester marketed by ASHLAND and corresponding to the following INCI
designation: Cl 2-C15 alkyl lactate;
¨ pinsolvTM EB and PG 22 marketed by INNOSPEC and corresponding respectively to the following INCI designations: ethylhexyl benzoate and dipropylene glycol dibenzoate;
¨ CRODAMOLTm DA, DOA, OSU and PC marketed by CRODA and corresponding respectively to the following INCI designations: diisopropyl adipate, diethylhexyl adipate, diethylhexyl suce mate and propylene glycol dicaprylate/dicaprate;
¨ ELDEWTM SL-205 marketed by AJINOMOTO and corresponding to the following INCI
designation: isopropyl lauroyl sarcosinate;
¨ LexfeelTM Shine marketed by INOLEX and corresponding to the INCI
designation: propylene glycol dibenzoate;
¨ TEGOSOFTTm XC marketed by EVONIK and corresponding to the following INCI
designation: phenoxyethyl caprylate;
¨ RONACARETm AP marketed by MERCK KGaA and corresponding to the following INCI
designation: hydroxyl dimethoxybenzyl malonate;
¨ DERMOLTm IDSA marketed by Alzo INTL and corresponding to the following INCI
designation: isodecyl salicylate;
¨ SpectrasolvTM DMDA marketed by Hallstar and corresponding to the following INCI
designation: dimethyl capramide;
¨ X-TENDTm 226 marketed by Ashland and corresponding to the following INCI
designation:
phenethyl benzoate.
According to a particular embodiment, the composition according to the invention comprises at least three solubilizers chosen from the group comprising the compounds corresponding to the following INCI designations: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco-caprylate, C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate.
According to a particular embodiment, the composition according to the invention comprises at least
¨ CeraphylTM 41 ester marketed by ASHLAND and corresponding to the following INCI
designation: Cl 2-C15 alkyl lactate;
¨ pinsolvTM EB and PG 22 marketed by INNOSPEC and corresponding respectively to the following INCI designations: ethylhexyl benzoate and dipropylene glycol dibenzoate;
¨ CRODAMOLTm DA, DOA, OSU and PC marketed by CRODA and corresponding respectively to the following INCI designations: diisopropyl adipate, diethylhexyl adipate, diethylhexyl suce mate and propylene glycol dicaprylate/dicaprate;
¨ ELDEWTM SL-205 marketed by AJINOMOTO and corresponding to the following INCI
designation: isopropyl lauroyl sarcosinate;
¨ LexfeelTM Shine marketed by INOLEX and corresponding to the INCI
designation: propylene glycol dibenzoate;
¨ TEGOSOFTTm XC marketed by EVONIK and corresponding to the following INCI
designation: phenoxyethyl caprylate;
¨ RONACARETm AP marketed by MERCK KGaA and corresponding to the following INCI
designation: hydroxyl dimethoxybenzyl malonate;
¨ DERMOLTm IDSA marketed by Alzo INTL and corresponding to the following INCI
designation: isodecyl salicylate;
¨ SpectrasolvTM DMDA marketed by Hallstar and corresponding to the following INCI
designation: dimethyl capramide;
¨ X-TENDTm 226 marketed by Ashland and corresponding to the following INCI
designation:
phenethyl benzoate.
According to a particular embodiment, the composition according to the invention comprises at least three solubilizers chosen from the group comprising the compounds corresponding to the following INCI designations: caprylyl caprylate/caprate, dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate, dicaprylyl ether, coco-caprylate, C12-15 alkyl benzoate, propylheptyl caprylate, butylene glycol dicaprylate/dicaprate.
According to a particular embodiment, the composition according to the invention comprises at least
21 the solubilizers corresponding to the following INCI designations: dibutyl adipate, dicaprylyl carbonate and diisopropyl sebacate.
According to another embodiment, the composition according to the invention comprises at least the solubilizers corresponding to the following INCI designations: dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate and propylheptyl caprylate.
According to a particular embodiment, the solubilizers represent between 5%
and 80% by mass relative to the total mass of the composition, advantageously between 10% and 70%, preferably between 15% and 60%.
According to a particular embodiment, the composition according to the invention comprises minera!
screens (or inorganic mineral screening agents), which correspond to metal oxides and/or other compounds that are poorly soluble or insoluble in water, in particular oxides titanium (TiO2), zinc (Zn0), iron (Fe2O3), zirconium (ZrO2), silicon (SiO2), manganese (e.g., MnO), aluminum (A1203), or cerium (Ce203), or bismuth trioxide (Bi203).
Inorganic minerai screening agents may also be surface-treated or encapsulated in order to give them a hydrophilic, amphiphilic or hydrophobic character. This surface treatment may consist of providing the mineral screening agents with a thin hydrophilic and/or hydrophobie inorganic and/or organic film.
According to a particular embodiment, the composition according to the invention comprises at least one minerai screen chosen from the group comprising the compounds corresponding to the following INCI designations: zinc oxide, titanium dioxide and mixtures thereof.
For example, zinc oxide corresponds to the Z-COTE LSA raw material and titanium dioxide to the T-Lite raw material, marketed by BASF.
The lists of UV screening agents cited which may be implemented within the meaning of the present invention are, obviously, given by way of example but not limited thereto.
According to a particular embodiment, the composition according to the invention has a sun protection factor called "SPF" equal to or greater than 20, advantageously equal to or greater than 30, preferably
According to another embodiment, the composition according to the invention comprises at least the solubilizers corresponding to the following INCI designations: dibutyl adipate, dicaprylyl carbonate, diisopropyl sebacate and propylheptyl caprylate.
According to a particular embodiment, the solubilizers represent between 5%
and 80% by mass relative to the total mass of the composition, advantageously between 10% and 70%, preferably between 15% and 60%.
According to a particular embodiment, the composition according to the invention comprises minera!
screens (or inorganic mineral screening agents), which correspond to metal oxides and/or other compounds that are poorly soluble or insoluble in water, in particular oxides titanium (TiO2), zinc (Zn0), iron (Fe2O3), zirconium (ZrO2), silicon (SiO2), manganese (e.g., MnO), aluminum (A1203), or cerium (Ce203), or bismuth trioxide (Bi203).
Inorganic minerai screening agents may also be surface-treated or encapsulated in order to give them a hydrophilic, amphiphilic or hydrophobic character. This surface treatment may consist of providing the mineral screening agents with a thin hydrophilic and/or hydrophobie inorganic and/or organic film.
According to a particular embodiment, the composition according to the invention comprises at least one minerai screen chosen from the group comprising the compounds corresponding to the following INCI designations: zinc oxide, titanium dioxide and mixtures thereof.
For example, zinc oxide corresponds to the Z-COTE LSA raw material and titanium dioxide to the T-Lite raw material, marketed by BASF.
The lists of UV screening agents cited which may be implemented within the meaning of the present invention are, obviously, given by way of example but not limited thereto.
According to a particular embodiment, the composition according to the invention has a sun protection factor called "SPF" equal to or greater than 20, advantageously equal to or greater than 30, preferably
22 equal to or greater than 40, or even equal to or greater than 50.
According to a preferred embodiment, the composition according to the invention comprises a UVA/UVB protection ratio equal fo or greater than 1/3.
In particular, the composition according to the invention has a critical wavelength (Xc) greater than 370 nm. This value, which is determined by in vitro methods known to a person skilled in the art, corresponds to the wavelength for which the integral of the absorption spectrum curve starting at 290 nm reaches 90% of the integral between 290 and 400 nm.
The composition according to the invention may further comprise an SPF
"booster", i.e., an amplifying agent of the sun protection factor, and/or a photo-stabilizer, i.e., an ingredient which makes it possible to increase the SPF or to photostabilize the screening agents, such an ingredient not itself being considered as a solar screening agent. These boosters may include, for example:
¨ butyloctyl salicylate (INCI), photostabilizer advantageously representing between 0.01% and 10% by weight relative to the total weight of the composition, even more advantageously between 0.1% and 2%. This raw material is, for example, marketed by HALLSTAR
under the name HallbriteTM BHB;
¨ benzotriazolyl dodecyl p-cresol (INCI), photostabilizer advantageously representing between 0.01% and 10% by weight relative to the total weight of the composition, even more advantageously between 0.1% and 2%. This raw material is, for example, marketed by BASF
under the name TINOGARDTm TL;
¨ pongamol (INCI), a plant molecule absorbing UVAs, advantageously representing between 0.5 and 2% by weight relative to the total weight of the composition, even more advantageously of the order of 1%. For example, the raw material Pongamia Extract marketed by GIVAUDAN
may be used in the context of the present invention;
¨ ethylhexyl methoxycrylene (INCI), photostabilizer, solubilizer and SPF
"booster"
advantageously representing between 1% and 5% by weight relative to the total weight of the composition. The SolaStayTM Si raw material marketed by HALLSTAR may be used in the context of the present invention;
¨ a styrene acrylate copolymer (INCI: styrene/acrylate copolymer), preferably representing between 1% and 10% by weight relative to the total weight of the composition according to the invention. The SunSpheresTM H53 and SunSpheresTM PGL Polymer raw materials,
According to a preferred embodiment, the composition according to the invention comprises a UVA/UVB protection ratio equal fo or greater than 1/3.
In particular, the composition according to the invention has a critical wavelength (Xc) greater than 370 nm. This value, which is determined by in vitro methods known to a person skilled in the art, corresponds to the wavelength for which the integral of the absorption spectrum curve starting at 290 nm reaches 90% of the integral between 290 and 400 nm.
The composition according to the invention may further comprise an SPF
"booster", i.e., an amplifying agent of the sun protection factor, and/or a photo-stabilizer, i.e., an ingredient which makes it possible to increase the SPF or to photostabilize the screening agents, such an ingredient not itself being considered as a solar screening agent. These boosters may include, for example:
¨ butyloctyl salicylate (INCI), photostabilizer advantageously representing between 0.01% and 10% by weight relative to the total weight of the composition, even more advantageously between 0.1% and 2%. This raw material is, for example, marketed by HALLSTAR
under the name HallbriteTM BHB;
¨ benzotriazolyl dodecyl p-cresol (INCI), photostabilizer advantageously representing between 0.01% and 10% by weight relative to the total weight of the composition, even more advantageously between 0.1% and 2%. This raw material is, for example, marketed by BASF
under the name TINOGARDTm TL;
¨ pongamol (INCI), a plant molecule absorbing UVAs, advantageously representing between 0.5 and 2% by weight relative to the total weight of the composition, even more advantageously of the order of 1%. For example, the raw material Pongamia Extract marketed by GIVAUDAN
may be used in the context of the present invention;
¨ ethylhexyl methoxycrylene (INCI), photostabilizer, solubilizer and SPF
"booster"
advantageously representing between 1% and 5% by weight relative to the total weight of the composition. The SolaStayTM Si raw material marketed by HALLSTAR may be used in the context of the present invention;
¨ a styrene acrylate copolymer (INCI: styrene/acrylate copolymer), preferably representing between 1% and 10% by weight relative to the total weight of the composition according to the invention. The SunSpheresTM H53 and SunSpheresTM PGL Polymer raw materials,
23 marketed by DOW CHEMICALS, may be used in the context of the present invention;
¨ diethylhexyl syringylidene malonate (INCI), advantageously representing between 1% and 10% by weight relative to the total weight of the composition. The raw material OXYNETTm ST, marketed by MERCK, may be used in the context of the present invention;
¨ a water-dispersible polyester, corresponding to the INCI designations:
polyester-5 (and) Sodium silicoaluminate, advantageously representing between 1% and 10% by weight relative to the total weight of the composition, in particular EASTMANN AQTM38S Polymer marketed by SAFIC-ALCAN;
¨
an acrylate copolymer having a glass transition temperature of -5 C
to -15 C as measured by differential scanning calorimetry, said copolymer advantageously representing between 1%
and 10% by weight relative to the total weight of the composition. For example, a polymer corresponding to the INCI designation: Acrylate copolymer, such as the raw material EPITEX
66, marketed by DOW CHEMICALS, may be used in the context of the present invention.
In a preferred embodiment, the composition according to the invention further comprises other components which may contribute to internat protection by an action which may consist of a DNA
protection, a reduction in immunosuppression induced by UV radiation, an anti-radical action or a combined effect of these actions.
The protective action of a composition according to the invention against oxidative stress or against the effect of free radicals may be further improved if it further comprises one or more antioxidants, easily selected by a person skilled in the art, for example, in the following list: totarol, magnolol, honokiol, amino acids and their derivatives, peptides (D and/or L-carnosine) and their derivatives (for example anserine, 1 hypotaurine, taurine), carotenoids, carotenes (a-carotene, 13-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (dihydrolipoic acid), aurothioglucose , propylthiouracil and other thiols (thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, rlinoleic, cholesteryl and glyceryl esters) as well as salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives, sulfoximine compounds (buthionine sulfoximine, homocysteine sulfoximine, buthionine sulfones, pentu-, hexa- and heptathionine sulfoximine), chelating agents (such as a-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), a-hydroxy acids (such as citric, lactic, or malic acid), acid humic, bile acid, bile extracts, bilirubin, biliverdin, ethylenediamine pentasodium tetramethylene phosphonate and its derivatives, unsaturated
¨ diethylhexyl syringylidene malonate (INCI), advantageously representing between 1% and 10% by weight relative to the total weight of the composition. The raw material OXYNETTm ST, marketed by MERCK, may be used in the context of the present invention;
¨ a water-dispersible polyester, corresponding to the INCI designations:
polyester-5 (and) Sodium silicoaluminate, advantageously representing between 1% and 10% by weight relative to the total weight of the composition, in particular EASTMANN AQTM38S Polymer marketed by SAFIC-ALCAN;
¨
an acrylate copolymer having a glass transition temperature of -5 C
to -15 C as measured by differential scanning calorimetry, said copolymer advantageously representing between 1%
and 10% by weight relative to the total weight of the composition. For example, a polymer corresponding to the INCI designation: Acrylate copolymer, such as the raw material EPITEX
66, marketed by DOW CHEMICALS, may be used in the context of the present invention.
In a preferred embodiment, the composition according to the invention further comprises other components which may contribute to internat protection by an action which may consist of a DNA
protection, a reduction in immunosuppression induced by UV radiation, an anti-radical action or a combined effect of these actions.
The protective action of a composition according to the invention against oxidative stress or against the effect of free radicals may be further improved if it further comprises one or more antioxidants, easily selected by a person skilled in the art, for example, in the following list: totarol, magnolol, honokiol, amino acids and their derivatives, peptides (D and/or L-carnosine) and their derivatives (for example anserine, 1 hypotaurine, taurine), carotenoids, carotenes (a-carotene, 13-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (dihydrolipoic acid), aurothioglucose , propylthiouracil and other thiols (thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, rlinoleic, cholesteryl and glyceryl esters) as well as salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives, sulfoximine compounds (buthionine sulfoximine, homocysteine sulfoximine, buthionine sulfones, pentu-, hexa- and heptathionine sulfoximine), chelating agents (such as a-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), a-hydroxy acids (such as citric, lactic, or malic acid), acid humic, bile acid, bile extracts, bilirubin, biliverdin, ethylenediamine pentasodium tetramethylene phosphonate and its derivatives, unsaturated
24 fatty acids and their derivatives, vitamin A and its derivatives (vitamin A
palmitate), coniferyl benzoate from benzoin resin, rutinic acid and its derivatives, a-glycosyl rutin, ferulic acid and its derivatives, furfurylideneglucitol, carnosine, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaretic acid, trihydroxybutyrophenone, quercetin, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (ZnO, ZnSO4), selenium and its derivatives (selenomethionine), stilbenes and their derivatives (1 stilbene oxide, trans-stilbene oxide).
In a particular embodiment, the composition according to the invention further comprises glycyrrhetinic acid, a derivative or sait of this acid, used as a soothing (anti-inflammatory agent) and representing between 0.01% and 2% by weight relative to the total weight of the composition, preferably between 0.1% and 1%.
According to another preferred characteristic of the invention, the cosmetic and/or dermatological composition comprises at least one, or even ail, of the following constituents exerting a biological activity in vivo on the cells of the skin, lips, hair and/or mucous membranes subjected to UVA and/or UVB radiation, respectively:
¨ an anti-radical agent preserving cellular structures, such as, for example, vitamin E and/or its lipid-soluble or water-soluble derivatives, in particular tocotrienol and/or tocopherol, advantageously representing between 0.001 and 10% by weight relative to the total weight of the composition, even more advantageously between 0.02 and 2%, preferably of the order of 0.04%;
¨ an agent limiting immunosuppression, such as, for example, vitamin PP, advantageously representing between 0.001 and 1% by weight relative to the total weight of the composition, even more advantageously from 0.01% to 0.3%;
¨ a protective agent for the p53 protein, such as, for example, epigallocatechin gallate (EGCG), advantageously representing between 0.001 and 0.1% by weight relative to the total weight of the composition, even more advantageously from 0.005% to 0,05%.
The composition according to the invention may further comprise, in addition, peptide extracts of soya and/or wheat, such as those described in document EP 2 059 230.
In practice, the peptide extracts, which come from soybean and wheat seeds, are the result of enzymatic hydrolysis of said seeds using peptidases which make it possible to recover peptides with an average
palmitate), coniferyl benzoate from benzoin resin, rutinic acid and its derivatives, a-glycosyl rutin, ferulic acid and its derivatives, furfurylideneglucitol, carnosine, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaretic acid, trihydroxybutyrophenone, quercetin, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (ZnO, ZnSO4), selenium and its derivatives (selenomethionine), stilbenes and their derivatives (1 stilbene oxide, trans-stilbene oxide).
In a particular embodiment, the composition according to the invention further comprises glycyrrhetinic acid, a derivative or sait of this acid, used as a soothing (anti-inflammatory agent) and representing between 0.01% and 2% by weight relative to the total weight of the composition, preferably between 0.1% and 1%.
According to another preferred characteristic of the invention, the cosmetic and/or dermatological composition comprises at least one, or even ail, of the following constituents exerting a biological activity in vivo on the cells of the skin, lips, hair and/or mucous membranes subjected to UVA and/or UVB radiation, respectively:
¨ an anti-radical agent preserving cellular structures, such as, for example, vitamin E and/or its lipid-soluble or water-soluble derivatives, in particular tocotrienol and/or tocopherol, advantageously representing between 0.001 and 10% by weight relative to the total weight of the composition, even more advantageously between 0.02 and 2%, preferably of the order of 0.04%;
¨ an agent limiting immunosuppression, such as, for example, vitamin PP, advantageously representing between 0.001 and 1% by weight relative to the total weight of the composition, even more advantageously from 0.01% to 0.3%;
¨ a protective agent for the p53 protein, such as, for example, epigallocatechin gallate (EGCG), advantageously representing between 0.001 and 0.1% by weight relative to the total weight of the composition, even more advantageously from 0.005% to 0,05%.
The composition according to the invention may further comprise, in addition, peptide extracts of soya and/or wheat, such as those described in document EP 2 059 230.
In practice, the peptide extracts, which come from soybean and wheat seeds, are the result of enzymatic hydrolysis of said seeds using peptidases which make it possible to recover peptides with an average
25 size of 700 Daltons. Preferably, the soy peptide extract is the extract identified under the CAS number 68607-88-5, just as the wheat peptide extract is the extract identified under the CAS number 70084-87-6. Wheat and soy extracts may correspond respectively to the following INCI
designations:
hydrolyzed wheat protein and hydrolyzed soy protein.
In a particular embodiment, the peptide extracts of soya ancVor wheat are used together, for example in a weight ratio respectively between 80/20 and 20/80, advantageously between 70/30 and 30/70, of preferably equal to 60/40.
In a particular embodiment, the peptide extracts of soy and/or wheat are free of synthetic GHK (glycyl-histidyl-lysine; INCI: Tripeptide-1) tripeptides. In practice, the peptide extracts of soya and/or wheat represent from 0.01 to 20% by weight relative to the total weight of the composition, advantageously from 0.1% to 10%, even more advantageously from 0.2% to 0.7%.
In an alternative embodiment, the composition according to the invention comprises, in accordance with the teachings of document FR 2 865 398, the association of at least one amino acid chosen from the group consisting of ectoine, creatine, ergothioneine and/or camosine, or their physiologically acceptable salts, and mannitol or a mannitol derivative.
Preferably, the composition according to the invention comprises, in a physiologically acceptable medium, the amino acid or one of its salts, alone or as a mixture in proportions of between 0.001%
and 10% by weight relative to the total weight of the composition, and preferably between 0.01% and 5%.
The composition according to the present invention preferably comprises, in a physiologically acceptable medium, mannitol or one of its derivatives, in proportions of between 0.01% and 30% by weight relative to the total weight of the composition, advantageously between 0.1% and 10%.
In a preferred embodiment, the composition according to the invention comprises ectoine and mannitol.
According to a particular embodiment, the composition according to the invention comprises one or more other tanning or self-tanning agents. It may be a self-tanner which reacts with the amino acids
designations:
hydrolyzed wheat protein and hydrolyzed soy protein.
In a particular embodiment, the peptide extracts of soya ancVor wheat are used together, for example in a weight ratio respectively between 80/20 and 20/80, advantageously between 70/30 and 30/70, of preferably equal to 60/40.
In a particular embodiment, the peptide extracts of soy and/or wheat are free of synthetic GHK (glycyl-histidyl-lysine; INCI: Tripeptide-1) tripeptides. In practice, the peptide extracts of soya and/or wheat represent from 0.01 to 20% by weight relative to the total weight of the composition, advantageously from 0.1% to 10%, even more advantageously from 0.2% to 0.7%.
In an alternative embodiment, the composition according to the invention comprises, in accordance with the teachings of document FR 2 865 398, the association of at least one amino acid chosen from the group consisting of ectoine, creatine, ergothioneine and/or camosine, or their physiologically acceptable salts, and mannitol or a mannitol derivative.
Preferably, the composition according to the invention comprises, in a physiologically acceptable medium, the amino acid or one of its salts, alone or as a mixture in proportions of between 0.001%
and 10% by weight relative to the total weight of the composition, and preferably between 0.01% and 5%.
The composition according to the present invention preferably comprises, in a physiologically acceptable medium, mannitol or one of its derivatives, in proportions of between 0.01% and 30% by weight relative to the total weight of the composition, advantageously between 0.1% and 10%.
In a preferred embodiment, the composition according to the invention comprises ectoine and mannitol.
According to a particular embodiment, the composition according to the invention comprises one or more other tanning or self-tanning agents. It may be a self-tanner which reacts with the amino acids
26 of the skin according to a Maillard reaction or through a Michael addition, or a promoter of melanogenesis or a propigmenting compound which promotes the natural tanning process of the skin.
Such a tanning or self-tanning agent is preferably present in the composition in an amount ranging from 0.01% to 20% by weight relative to the total weight of the composition, advantageously from 0.5% to 15%, even more advantageously from 1% at 8%.
Self-tanning substances may be 1,3-dihydroxyacetone (DHA), glycerolaldehyde, hydroxymethylglyoxal, y-dialdehyde, erythrulose, 6-aldo-D-fructose, ninhydrin, 5-hydroxy-1,4-naphthoquinone (juglone), 2-hydroxy-1,4-naphthoquinone (lawsone), or a combination thereof.
The propigmenting substances may be melanocyte-stimulating hormone (ci-MSH), peptide analogs of a-MSH, endothelin-1 receptor agonists, j.t-opioid receptor agonists, cAMP
stimulators, or tyrosinase stimulators.
In a particular embodiment, the composition according to the invention further comprises, as a self-tanner, a combination of dihydroxy methylchromonyl palmitate and/or dimethylmethoxy chromanol, as well as a lipophilic form of tyrosine.
This combination of active ingredients effectively stimulates tanning.
Dihydroxy methylchromonyl palmitate (CAS number: 1387636-35-2) corresponds, for example, to the cosmetic ingredient marketed by MERCK under the name RonaCareTM Bronzyl. Dimethylmethoxy chromanol (CAS
number: 83923-51-7) corresponds, for example, to the cosmetic ingredient marketed by LIPOTEC SA
under the name lipochromone-6.
According to a particular embodiment, dihydroxy methylchromonyl palmitate or dimethylmethoxy chromanol is included in the composition according to the invention in an amount of 0.01% to 10%
by weight relative to the total weight of the composition, advantageously 0.05% to 10%, even more advantageously from 0.1% to 5%, more particularly from 0.1% to 0.5%.
Within the meaning of the invention, the lipophilic form of tyrosine is an tyrosine-based ingredient that has a more pronounced lipophilic character than tyrosine. The lipophilic form of tyrosine may, in particular, correspond to oleoyl tyrosine (CAS number: 147732-57-8), which is found, for example,
Such a tanning or self-tanning agent is preferably present in the composition in an amount ranging from 0.01% to 20% by weight relative to the total weight of the composition, advantageously from 0.5% to 15%, even more advantageously from 1% at 8%.
Self-tanning substances may be 1,3-dihydroxyacetone (DHA), glycerolaldehyde, hydroxymethylglyoxal, y-dialdehyde, erythrulose, 6-aldo-D-fructose, ninhydrin, 5-hydroxy-1,4-naphthoquinone (juglone), 2-hydroxy-1,4-naphthoquinone (lawsone), or a combination thereof.
The propigmenting substances may be melanocyte-stimulating hormone (ci-MSH), peptide analogs of a-MSH, endothelin-1 receptor agonists, j.t-opioid receptor agonists, cAMP
stimulators, or tyrosinase stimulators.
In a particular embodiment, the composition according to the invention further comprises, as a self-tanner, a combination of dihydroxy methylchromonyl palmitate and/or dimethylmethoxy chromanol, as well as a lipophilic form of tyrosine.
This combination of active ingredients effectively stimulates tanning.
Dihydroxy methylchromonyl palmitate (CAS number: 1387636-35-2) corresponds, for example, to the cosmetic ingredient marketed by MERCK under the name RonaCareTM Bronzyl. Dimethylmethoxy chromanol (CAS
number: 83923-51-7) corresponds, for example, to the cosmetic ingredient marketed by LIPOTEC SA
under the name lipochromone-6.
According to a particular embodiment, dihydroxy methylchromonyl palmitate or dimethylmethoxy chromanol is included in the composition according to the invention in an amount of 0.01% to 10%
by weight relative to the total weight of the composition, advantageously 0.05% to 10%, even more advantageously from 0.1% to 5%, more particularly from 0.1% to 0.5%.
Within the meaning of the invention, the lipophilic form of tyrosine is an tyrosine-based ingredient that has a more pronounced lipophilic character than tyrosine. The lipophilic form of tyrosine may, in particular, correspond to oleoyl tyrosine (CAS number: 147732-57-8), which is found, for example,
27 in the liquid cosmetic ingredient TYR-OL, marketed by SEDERMA, and which comprises approximately 50% by weight of oleoyl tyrosine in butylene glycol (approximately 30% +
approximately 20% oleic acid), or in the liquid cosmetic ingredient TYR-EXCEL, marketed by SEDERMA, which comprises approximately 50% by weight of oleoyl tyrosine, approximately 20%
by weight of oleic acid (CAS No.: 112-80-1) and approximately 30% by weight of Luffa cylindrica oil (sponge pumpkin seed oil; No. CAS: 1242417-48-6).
According to another embodiment, the lipophilic form of tyrosine corresponds to a vegetable oil in which the tyrosine has been formulated.
According to a particular embodiment, the vegetable oil is oleic sunflower oil, in particular deodorized.
Thus, the OLEOACTIVE TYROSINE BASED HELIANTHUS ANNUS raw material marketed by OLEOS, and corresponding to the INCI designations: Helianthus annuus seed oil (and) tyrosine (and) glyceryl stearate, may be used in the context of the present invention.
In practice, the lipophilic form of tyrosine, such as in oleoyl-tyrosine-based cosmetic ingredients (advantageously at 50% by weight) or tyrosine formulated in vegetable oil, represents between 0.1%
and 10% by weight relative to the total weight of the composition, advantageously between 1 and 3%, even more advantageously between 1% and 1.5%.
The composition according to the invention may further comprise active ingredients having depigmenting properties, such as, for example:
¨ lysine azeilate, or other derivatives or salts of azelaic acid;
¨ andrographolide, in particular the extract of Andrographis paniculata corresponding to the INCI designation: Andrographis panieulata leaf extract;
¨ native ascorbic acid (vitamin C) or its derivatives, in particular the derivatives corresponding to the INCI designations: ascorbyl glucoside, ethyl ascorbic acid, ascorbyl methylsilanol pectinate, sodium ascorbyl phosphate and ascorbyl tetraisopalmitate, advantageously ascorbyl glucoside;
¨ arbutin or a plant extract containing it, in particular bearberry extract corresponding to the INCI
designation: Arctostaphylos uva-ursi leaf extract;
¨ glabridin or a plant extract containing it, in particular licorice extracts corresponding to the INCI designation: Glycyrrhiza glabra root extract, Glycyrrhiza frelata root extract,
approximately 20% oleic acid), or in the liquid cosmetic ingredient TYR-EXCEL, marketed by SEDERMA, which comprises approximately 50% by weight of oleoyl tyrosine, approximately 20%
by weight of oleic acid (CAS No.: 112-80-1) and approximately 30% by weight of Luffa cylindrica oil (sponge pumpkin seed oil; No. CAS: 1242417-48-6).
According to another embodiment, the lipophilic form of tyrosine corresponds to a vegetable oil in which the tyrosine has been formulated.
According to a particular embodiment, the vegetable oil is oleic sunflower oil, in particular deodorized.
Thus, the OLEOACTIVE TYROSINE BASED HELIANTHUS ANNUS raw material marketed by OLEOS, and corresponding to the INCI designations: Helianthus annuus seed oil (and) tyrosine (and) glyceryl stearate, may be used in the context of the present invention.
In practice, the lipophilic form of tyrosine, such as in oleoyl-tyrosine-based cosmetic ingredients (advantageously at 50% by weight) or tyrosine formulated in vegetable oil, represents between 0.1%
and 10% by weight relative to the total weight of the composition, advantageously between 1 and 3%, even more advantageously between 1% and 1.5%.
The composition according to the invention may further comprise active ingredients having depigmenting properties, such as, for example:
¨ lysine azeilate, or other derivatives or salts of azelaic acid;
¨ andrographolide, in particular the extract of Andrographis paniculata corresponding to the INCI designation: Andrographis panieulata leaf extract;
¨ native ascorbic acid (vitamin C) or its derivatives, in particular the derivatives corresponding to the INCI designations: ascorbyl glucoside, ethyl ascorbic acid, ascorbyl methylsilanol pectinate, sodium ascorbyl phosphate and ascorbyl tetraisopalmitate, advantageously ascorbyl glucoside;
¨ arbutin or a plant extract containing it, in particular bearberry extract corresponding to the INCI
designation: Arctostaphylos uva-ursi leaf extract;
¨ glabridin or a plant extract containing it, in particular licorice extracts corresponding to the INCI designation: Glycyrrhiza glabra root extract, Glycyrrhiza frelata root extract,
28 Glycyrrhiza uralensis root extract;
¨ biomimetic peptides corresponding to the INCI designations: hexapeptide 2 and/or nonapeptide-1;
¨ an aqueous extract of an algae called Palmaria palmata, in particular the extract corresponding to the INCI designation: Palmaria palmata extract;
¨ 4-n-butylresorcinol;
¨ vitamin PP, also called niacinamide or nicotinamide, and its derivatives;
¨ or mixtures thereof.
The composition according to the invention may further comprise active ingredients having healing properties such as, for example, an antimicrobial agent chosen from active ingredients corresponding to the following INCI designations: copper sulfate, zinc sulfate, sodium hyaluronate, Vitis vinifera (grape) vine extract and mixtures thereof.
The composition according to the invention may further comprise active ingredients having sebocorrective, keratolytic, seboregulatory properties and/or anti-acne activity, in order to allow the formulation of solar screening agent products treating acne.
For example, the composition according to the invention may comprise an antimicrobial agent chosen from active ingredients corresponding to the following INCI designations:
propyl gallate, dodecyl gallate, Ginkgo biloba leaf extract, bakuchiol, dihydromyricetin, zinc gluconate, salicylic acid and mixtures thereof.
Therefore, the composition according to the invention may further comprise at least one ingredient chosen from the following list:
¨ an agent capable of screening agenting visible light, in particular blue light;
¨ an extract of the algae Laminaria ochroleuca, Blidingia minima or Laminaria saccharina;
¨ an extract of the Zanthoxylum alatum plant;
¨ panthenol;
¨ a cade wood extract;
¨ a Boldo extract;
¨ a meadowsweet extract;
¨ biomimetic peptides corresponding to the INCI designations: hexapeptide 2 and/or nonapeptide-1;
¨ an aqueous extract of an algae called Palmaria palmata, in particular the extract corresponding to the INCI designation: Palmaria palmata extract;
¨ 4-n-butylresorcinol;
¨ vitamin PP, also called niacinamide or nicotinamide, and its derivatives;
¨ or mixtures thereof.
The composition according to the invention may further comprise active ingredients having healing properties such as, for example, an antimicrobial agent chosen from active ingredients corresponding to the following INCI designations: copper sulfate, zinc sulfate, sodium hyaluronate, Vitis vinifera (grape) vine extract and mixtures thereof.
The composition according to the invention may further comprise active ingredients having sebocorrective, keratolytic, seboregulatory properties and/or anti-acne activity, in order to allow the formulation of solar screening agent products treating acne.
For example, the composition according to the invention may comprise an antimicrobial agent chosen from active ingredients corresponding to the following INCI designations:
propyl gallate, dodecyl gallate, Ginkgo biloba leaf extract, bakuchiol, dihydromyricetin, zinc gluconate, salicylic acid and mixtures thereof.
Therefore, the composition according to the invention may further comprise at least one ingredient chosen from the following list:
¨ an agent capable of screening agenting visible light, in particular blue light;
¨ an extract of the algae Laminaria ochroleuca, Blidingia minima or Laminaria saccharina;
¨ an extract of the Zanthoxylum alatum plant;
¨ panthenol;
¨ a cade wood extract;
¨ a Boldo extract;
¨ a meadowsweet extract;
29 ¨ an extract of karanja ou l from Pongamia glabra;
¨ linear paraffins;
¨ ATP (adenosine-5 tri-phosphate), Gp4G (diguanosine tetraphosphate) or Ap4A (diadenosine tetraphosphate), ¨ an amino acid chosen from the group consisting of decarboxycarnosine, glutamine and their salts.
The composition according to the invention may further comprise adjuvants such as those usually used in the field of cosmetics, such as preservatives, antioxidants, complexing agents, solvents, perfumes, fillers, bactericides, electrolytes, odor absorbers, coloring materials or even lipid vesicles. The choice of these adjuvants, as well as their concentrations, must be determined in order to prevent them from modifying the properties and advantages sought for the composition of the present invention.
The composition of the invention is for topical application and, more particularly, for application to the skin, lips, hair and/or mucous membranes. Thus, and in the context of the invention, such a composition is intended, in particular, for the protection of the skin and/or integuments, in particular the mucous membranes, lips and hair, against UV radiation.
The composition of the invention may be presented in ail the galenic forms normally used in the cosmetic and dermatological fields, such as, for example, but flot limited to, in the forrn of an aqueous solution optionally gelled, a dispersion of the lotion type, a more or less fluid 0/W or, conversely, W/O emulsion, or a multiple emulsion such as, for example, a triple emulsion (W/O/W or 0/W/O), or even in the form of a vesicular dispersion of ionic (liposomes) and/or non-ionic type, a two-phase composition devoid of emulsifiers and gelling agents whose immiscible phases separate during storage, foam, stick, anhydrous oil, spray or mist.
In a preferred embodiment, the composition according to the invention is a W/O
emulsion. In a particular embodiment, the W/O emulsions according to the invention comprise dipolyhydroxystearate (INCI), or polyglycery1-4 diisostearate/polyhydroxystearate/sebacate as emulsifiers. These raw materials are available from CRODA under the trade name Cithrol DPHS and from EVONIK under the name Isolan GPS, respectively.
In an alternative embodiment, the composition according to the invention is an 0/W emulsion. In a
¨ linear paraffins;
¨ ATP (adenosine-5 tri-phosphate), Gp4G (diguanosine tetraphosphate) or Ap4A (diadenosine tetraphosphate), ¨ an amino acid chosen from the group consisting of decarboxycarnosine, glutamine and their salts.
The composition according to the invention may further comprise adjuvants such as those usually used in the field of cosmetics, such as preservatives, antioxidants, complexing agents, solvents, perfumes, fillers, bactericides, electrolytes, odor absorbers, coloring materials or even lipid vesicles. The choice of these adjuvants, as well as their concentrations, must be determined in order to prevent them from modifying the properties and advantages sought for the composition of the present invention.
The composition of the invention is for topical application and, more particularly, for application to the skin, lips, hair and/or mucous membranes. Thus, and in the context of the invention, such a composition is intended, in particular, for the protection of the skin and/or integuments, in particular the mucous membranes, lips and hair, against UV radiation.
The composition of the invention may be presented in ail the galenic forms normally used in the cosmetic and dermatological fields, such as, for example, but flot limited to, in the forrn of an aqueous solution optionally gelled, a dispersion of the lotion type, a more or less fluid 0/W or, conversely, W/O emulsion, or a multiple emulsion such as, for example, a triple emulsion (W/O/W or 0/W/O), or even in the form of a vesicular dispersion of ionic (liposomes) and/or non-ionic type, a two-phase composition devoid of emulsifiers and gelling agents whose immiscible phases separate during storage, foam, stick, anhydrous oil, spray or mist.
In a preferred embodiment, the composition according to the invention is a W/O
emulsion. In a particular embodiment, the W/O emulsions according to the invention comprise dipolyhydroxystearate (INCI), or polyglycery1-4 diisostearate/polyhydroxystearate/sebacate as emulsifiers. These raw materials are available from CRODA under the trade name Cithrol DPHS and from EVONIK under the name Isolan GPS, respectively.
In an alternative embodiment, the composition according to the invention is an 0/W emulsion. In a
30 particular embodiment, the 0/W emulsions according to the invention comprise an emulsifier chosen from the following group of compounds identified by their INCI designation:
sodium stearoyl glutamate, potassium cetyl phosphate, glyceryl stearate/PEG-100 stearate and C20-22 alkyl phosphate/C20-C22 alkyl alcohols, tribehenin PEG-20 esters, C14-C22 alcohols/C12-20 alkyl glucoside, cetearyl alcohol/coco-glucoside, polyglycery1-6 stearate, polyglycery1-6 behenate and mixtures thereof These raw materials are available from several suppliers. For example, EMULGIN
SG raw materials (INCI: sodium stearoyl glutamate; supplier: BASF); EMULIUM 22 (INCI:
tribehenin PEG-20 esters; supplier GATTEFOSSE); SENSANOV WR (INCI: C20-22 alkyl phosphate/C20-C22 alkyl alcohols; supplier: SEPPIC); MONTANOV L (INCI: C14-C22 alcohols/C12-20 alkyl glucoside), AMPHISOL K (INCI: potassium cetyl phosphate;
supplier: DSM), MONTANOV 82 (INCI: cetearyl alcohol/coco-glucoside; supplier: SEPPIC); TEGOTm Care PBS 6 MB (INCI: polyglycery1-6 stearate & polyglycery1-6 behenate; supplier: EVONIK) may be used in the compositions according to the invention.
According to another aspect, the invention relates to a composition as described above to be used for protection against ultraviolet solar radiation, in particular of wavelength between 100 and 400 nm.
According to a particular embodiment, the invention relates to a composition comprising:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI de signations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least one organic UVB screening agent or a broad-spectrum organic screening agent absorbing both UVBs and UVAs;
¨ at least one organic UVA screening agent;
to be used to protect the skin, mucous membranes and/or integuments against UV
radiation.
According to a particular embodiment, the composition according to the invention is used to screening agent UV radiation between 280 and 400 nm, in particular between 300 and 380 nm.
According to a particular embodiment, the invention relates to a composition comprising:
sodium stearoyl glutamate, potassium cetyl phosphate, glyceryl stearate/PEG-100 stearate and C20-22 alkyl phosphate/C20-C22 alkyl alcohols, tribehenin PEG-20 esters, C14-C22 alcohols/C12-20 alkyl glucoside, cetearyl alcohol/coco-glucoside, polyglycery1-6 stearate, polyglycery1-6 behenate and mixtures thereof These raw materials are available from several suppliers. For example, EMULGIN
SG raw materials (INCI: sodium stearoyl glutamate; supplier: BASF); EMULIUM 22 (INCI:
tribehenin PEG-20 esters; supplier GATTEFOSSE); SENSANOV WR (INCI: C20-22 alkyl phosphate/C20-C22 alkyl alcohols; supplier: SEPPIC); MONTANOV L (INCI: C14-C22 alcohols/C12-20 alkyl glucoside), AMPHISOL K (INCI: potassium cetyl phosphate;
supplier: DSM), MONTANOV 82 (INCI: cetearyl alcohol/coco-glucoside; supplier: SEPPIC); TEGOTm Care PBS 6 MB (INCI: polyglycery1-6 stearate & polyglycery1-6 behenate; supplier: EVONIK) may be used in the compositions according to the invention.
According to another aspect, the invention relates to a composition as described above to be used for protection against ultraviolet solar radiation, in particular of wavelength between 100 and 400 nm.
According to a particular embodiment, the invention relates to a composition comprising:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI de signations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least one organic UVB screening agent or a broad-spectrum organic screening agent absorbing both UVBs and UVAs;
¨ at least one organic UVA screening agent;
to be used to protect the skin, mucous membranes and/or integuments against UV
radiation.
According to a particular embodiment, the composition according to the invention is used to screening agent UV radiation between 280 and 400 nm, in particular between 300 and 380 nm.
According to a particular embodiment, the invention relates to a composition comprising:
31 ¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both UVBs and UVAs;
¨ -at least one organic UVA screening agent, to be used as a UV screening agenting agent, in particular for the wavelength spectrum between 280 and 400 nm, in particular between 300 and 380 nm.
According to a particular embodiment, the invention relates to the use of:
¨ at least one MAA as defined above, in particular chosen from the group consisting of those corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both UVBs and UVAs; with ¨ at least one organic UVA screening agent;
to be used for the preparation of a cosmetic composition.
The invention also relates to a cosmetic treatment process consisting of applying to the skin and to the integuments a composition comprising:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both UVBs and UVAs;
¨ -at least one organic UVA screening agent, to be used as a UV screening agenting agent, in particular for the wavelength spectrum between 280 and 400 nm, in particular between 300 and 380 nm.
According to a particular embodiment, the invention relates to the use of:
¨ at least one MAA as defined above, in particular chosen from the group consisting of those corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both UVBs and UVAs; with ¨ at least one organic UVA screening agent;
to be used for the preparation of a cosmetic composition.
The invention also relates to a cosmetic treatment process consisting of applying to the skin and to the integuments a composition comprising:
¨ at least one MAA as defined above, in particular chosen from the group consisting of the molecules corresponding to the INCI designations: methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as, optionally, the compound corresponding to CAS number 2699128-33-9;
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-
32 spectrum organic screening agents absorbing both UVBs and UVAs;
¨ at least one organic UVA screening agent.
The manner in which the invention may be carried out and the resulting advantages will become clearer from the following exemplary embodiments, given by way of example but flot limited thereto.
Exemplary embodiments of the invention In the tables below, the percentages indicated are given in mass of product relative to the total mass of the composition.
Example I ¨ Solar emulsion [Table 1]
Ingredients (INCI designation) Percentage (%) Aqua 52.70 Diethylamino hydroxybenzoyl hexyl benzoate (organic UVA solar 10.00 screening agent) Bis-ethylhexyloxyphenol methoxyphenyl triazine (broad-spectrum 3.50 organic solar screening agent) Diethylhexyl butamido triazone (broad-spectrum organic solar screening agent) Methoxyphenylimino dimethylhexahydro benzothiazine carboxylic 1.00 acid (MAA according to the invention) Hexyl laurate 10.00 Propanediol 5.00 C12-15 alkyl benzoate 4.00 Dicapryly1 carbonate 3.9988 Polyglycery1-6 stearate 2.2875
¨ at least one organic UVA screening agent.
The manner in which the invention may be carried out and the resulting advantages will become clearer from the following exemplary embodiments, given by way of example but flot limited thereto.
Exemplary embodiments of the invention In the tables below, the percentages indicated are given in mass of product relative to the total mass of the composition.
Example I ¨ Solar emulsion [Table 1]
Ingredients (INCI designation) Percentage (%) Aqua 52.70 Diethylamino hydroxybenzoyl hexyl benzoate (organic UVA solar 10.00 screening agent) Bis-ethylhexyloxyphenol methoxyphenyl triazine (broad-spectrum 3.50 organic solar screening agent) Diethylhexyl butamido triazone (broad-spectrum organic solar screening agent) Methoxyphenylimino dimethylhexahydro benzothiazine carboxylic 1.00 acid (MAA according to the invention) Hexyl laurate 10.00 Propanediol 5.00 C12-15 alkyl benzoate 4.00 Dicapryly1 carbonate 3.9988 Polyglycery1-6 stearate 2.2875
33 Glycerin 2.00 Microcrystalline cellulose 1.32 1,2-hexanediol 1.25 C20-22 alkyl phosphate 1.10 C20-22 alcohols 0.90 Caprylyl glycol 0.25 Polyglycery1-6 behenate 0.2125 Sodium citrate 0.20 Cellulose gum 0.18 Sodium hydroxide 0.06 Xanthan gum 0.04 Tocopherol 0.0012 Example II ¨ Solar emulsion [Table 2]
Ingredients (INCI designation) Percentage (%) Aqua 51.838 Homosalate (organic UVB solar screening agent) 9.00 Ethylhexyl methoxycrylene 6.30 Glycerin 5.00 Ethylhexyl salicylate (organic UVB solar screening agent) 4.50 Tribehenin PEG-20 esters 3.00 Silicon 3.00 Butyl methoxydibenzoylmethane (organic UVA solar screening 2.70 agent) C12-15 alkyl benzoate 2.50 Dimethicone 1.72
Ingredients (INCI designation) Percentage (%) Aqua 51.838 Homosalate (organic UVB solar screening agent) 9.00 Ethylhexyl methoxycrylene 6.30 Glycerin 5.00 Ethylhexyl salicylate (organic UVB solar screening agent) 4.50 Tribehenin PEG-20 esters 3.00 Silicon 3.00 Butyl methoxydibenzoylmethane (organic UVA solar screening 2.70 agent) C12-15 alkyl benzoate 2.50 Dimethicone 1.72
34 Butyloetyl salicylate 1.60 Methoxyphenylimino dimethylcyclohexene glycine (MAA
1.00 according to the invention) Benzotriazolyl dodecyl p-cresol 1.00 Caprylyloxyphenylamino dimethyltetrahydro benzothiazine 1.00 carboxylic acid (MAA according to the invention) Vp/eicosene copolymer 0.80 Cetearyl alcohol 0.80 C20-22 alkyl phosphate 0.55 PEU-100 stearate 0.50 Pentylene glycol 0.50 Glyceryl stearate 0.50 C20-22 alcohols 0.45 Hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer 0.396 Polysilic on 0.28 1,2-hexanediol 0.25 Caprylyl glycol 0.25 Xanthan gum 0.20 Sodium citrate 0.20 Pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate 0.05 Sodium hydroxide 0.042 Sorbitan isostearate 0.027 Polysorbate 60 0.027 Aminoethanesulfinie acid 0.02
1.00 according to the invention) Benzotriazolyl dodecyl p-cresol 1.00 Caprylyloxyphenylamino dimethyltetrahydro benzothiazine 1.00 carboxylic acid (MAA according to the invention) Vp/eicosene copolymer 0.80 Cetearyl alcohol 0.80 C20-22 alkyl phosphate 0.55 PEU-100 stearate 0.50 Pentylene glycol 0.50 Glyceryl stearate 0.50 C20-22 alcohols 0.45 Hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer 0.396 Polysilic on 0.28 1,2-hexanediol 0.25 Caprylyl glycol 0.25 Xanthan gum 0.20 Sodium citrate 0.20 Pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate 0.05 Sodium hydroxide 0.042 Sorbitan isostearate 0.027 Polysorbate 60 0.027 Aminoethanesulfinie acid 0.02
35 Example III ¨ Solar emulsion [Table 3]
Ingredients (INCI designation) Percentage (%) Aqua 57.948 Homosalate (organic UVB solar screening agent) 9.00 Ethylhexyl methoxycrylene 6.30 Glycerin 5.00 Dibutyl adipate 5.00 Butyl methoxydibenzoylmethane (organic UVA solar screening agent) 4.50 Ethylhexyl salicylate (organic UVB solar screening agent) 4.50 Potassium cetyl phosphate 3.00 Methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid (MAA according to the invention) 1.00 Sodium stearoyl glutamate 1.00 Cetearyl alcohol 0.80 Pentylene glycol 0.50 Hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer 0.396 Citric acid 0.302 Caprylyl glycol 0.25 1,2-hexanediol 0.25 Xanthan gum 0.20 Sorbitan isostearate 0.027 Polysorbate 60 0.027
Ingredients (INCI designation) Percentage (%) Aqua 57.948 Homosalate (organic UVB solar screening agent) 9.00 Ethylhexyl methoxycrylene 6.30 Glycerin 5.00 Dibutyl adipate 5.00 Butyl methoxydibenzoylmethane (organic UVA solar screening agent) 4.50 Ethylhexyl salicylate (organic UVB solar screening agent) 4.50 Potassium cetyl phosphate 3.00 Methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid (MAA according to the invention) 1.00 Sodium stearoyl glutamate 1.00 Cetearyl alcohol 0.80 Pentylene glycol 0.50 Hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer 0.396 Citric acid 0.302 Caprylyl glycol 0.25 1,2-hexanediol 0.25 Xanthan gum 0.20 Sorbitan isostearate 0.027 Polysorbate 60 0.027
36 Example IV ¨ Solar emulsion [Table 4]
Ingredients (INCI designation) Percentage (%) Aqua/water 48.70 Diethylamino hydroxybenzoyl hexyl benzoate (organic UVA
solar screening agent) 10.00 Hexyl laurate 10.00 Propanediol 5.00 C12-15 alkyl benzoate 4.00 Diethylhexyl butamido triazone (broad-spectrum organic solar screening agent) 4.00 Dicaprylyl carbonate 3.9988 Bis-ethylhexyloxyphenol methoxyphenyl triazine (broad-3.500 spectrum organic solar screening agent) Polyglycery1-6 stearate 2.2875 Glycerin 2.00 Microcrystalline cellulose 1.32 1,2-hexanediol 1.25 C20-22 alkyl phosphate 1.10 Methoxyphenylimino dimethylcyclohexenyl ethyl glycinate (MAA according to the invention) 1.00 C20-22 alcohols 0.90 Caprylyl glycol 0.25 Polyglycery1-6 behenate 0.2125
Ingredients (INCI designation) Percentage (%) Aqua/water 48.70 Diethylamino hydroxybenzoyl hexyl benzoate (organic UVA
solar screening agent) 10.00 Hexyl laurate 10.00 Propanediol 5.00 C12-15 alkyl benzoate 4.00 Diethylhexyl butamido triazone (broad-spectrum organic solar screening agent) 4.00 Dicaprylyl carbonate 3.9988 Bis-ethylhexyloxyphenol methoxyphenyl triazine (broad-3.500 spectrum organic solar screening agent) Polyglycery1-6 stearate 2.2875 Glycerin 2.00 Microcrystalline cellulose 1.32 1,2-hexanediol 1.25 C20-22 alkyl phosphate 1.10 Methoxyphenylimino dimethylcyclohexenyl ethyl glycinate (MAA according to the invention) 1.00 C20-22 alcohols 0.90 Caprylyl glycol 0.25 Polyglycery1-6 behenate 0.2125
37 Sodium citrate 0.20 Cellulose gum 0.18 Sodium hydroxide 0.06 Xanthan gum 0.04 Tocopherol 0.0012 Example V- Measurement of the sun protection factor (SPF) obtained with compositions according to the invention V-1 Objective of the study The objective of the study was the development of compositions with a so-called high sun protection factor (SPF), i.e., with an SPF>20, incorporating organic UV screening agents and MAAs according to the invention.
V-2 Materials and methods An in vitro method for measuring the sun protection factor was used. A first UV absorption measurement is carried out on a plate (molded PMMA plate or SB6 sandblasted plate, Helioscreen) covered with 15 1 of glycerin (white), which eliminates absorption by the support.
For Formula 1 and Formula 2, the measurements are carried out using HD6 molded plates, according to the following protocol.
Then, the product studied is taken and deposited in 16 spots on the HD6 molded PMMA plate from Helioscreen (5*5cm). The weighed quantity is 32.5 mg, which corresponds to a concentration of 1.3 mg/cm2. The sample is spread uniformly using a spreading robot (HD-SPREADMASTER -Helioscreen). The plate is then placed in the dark at room temperature for at least 15 min. The plate is introduced into the measuring chamber of the Labsphère UV 2000 S
spectrophotometer, to carry out UV absorption measurements between 290 and 400 nm. It should be noted that a measurement actually
V-2 Materials and methods An in vitro method for measuring the sun protection factor was used. A first UV absorption measurement is carried out on a plate (molded PMMA plate or SB6 sandblasted plate, Helioscreen) covered with 15 1 of glycerin (white), which eliminates absorption by the support.
For Formula 1 and Formula 2, the measurements are carried out using HD6 molded plates, according to the following protocol.
Then, the product studied is taken and deposited in 16 spots on the HD6 molded PMMA plate from Helioscreen (5*5cm). The weighed quantity is 32.5 mg, which corresponds to a concentration of 1.3 mg/cm2. The sample is spread uniformly using a spreading robot (HD-SPREADMASTER -Helioscreen). The plate is then placed in the dark at room temperature for at least 15 min. The plate is introduced into the measuring chamber of the Labsphère UV 2000 S
spectrophotometer, to carry out UV absorption measurements between 290 and 400 nm. It should be noted that a measurement actually
38 corresponds to the average of 9 measurements (9 points on the PMMA plate are measured).
In the cases of Formula 3 to Formula 7, the protocol is identical but SB6 sandblasted plates are used.
For these plates, the weighed quantity is 30 mg, which corresponds to a concentration of 1.2 mg/cm2.
Theoretical SPFs are calculated for individual screening agents, because in vitro SPF cannot be measured under these conditions. The BASF simulator is used for these measurements (Herzog et al.
2003).
The following formulas are created and tested:
[Table 5]
Percentage (%) Ingredients (INCI designation) Formula 1 Formula (formula according to the invention) Water 52.70 48.70 Diethylamino hydroxybenzoyl hexyl 10.00 10.00 benzoate (UVA screening agent) Bis-ethylhexyloxyphenol methoxyphenyl triazine (broad-spectrum screening 3.50 3.50 agent) Diethylhexyl butamido triazone (broad-- 4.00 spectrum screening agent) Methoxyphenylimino dimethylcyclohexene glycine (MAA 1.00 1.00 according to the invention) Hexyllaurate 10.00 10.00
In the cases of Formula 3 to Formula 7, the protocol is identical but SB6 sandblasted plates are used.
For these plates, the weighed quantity is 30 mg, which corresponds to a concentration of 1.2 mg/cm2.
Theoretical SPFs are calculated for individual screening agents, because in vitro SPF cannot be measured under these conditions. The BASF simulator is used for these measurements (Herzog et al.
2003).
The following formulas are created and tested:
[Table 5]
Percentage (%) Ingredients (INCI designation) Formula 1 Formula (formula according to the invention) Water 52.70 48.70 Diethylamino hydroxybenzoyl hexyl 10.00 10.00 benzoate (UVA screening agent) Bis-ethylhexyloxyphenol methoxyphenyl triazine (broad-spectrum screening 3.50 3.50 agent) Diethylhexyl butamido triazone (broad-- 4.00 spectrum screening agent) Methoxyphenylimino dimethylcyclohexene glycine (MAA 1.00 1.00 according to the invention) Hexyllaurate 10.00 10.00
39 Propanediol 5.00 5.00 C12-15 alkyl benzoate 4.00 4.00 Dicaprylyl carbonate 3.9988 3.9988 Polyglycery1-6 stearate 2.2875 2.2875 Glycerin 2.00 2.00 Microcrystalline cellulose 1.32 1.32 1,2-hexanediol 1.25 1.25 C20-22 alkyl phosphate 1.10 1.10 C20-22 alcohols 0.90 0.90 Caprylyl glycol 0.25 0.25 Polyglycery1-6 behenate 0.2125 0.2125 Sodium citrate 0.20 0.20 Cellulose gum 0.18 0.18 Sodium hydroxide 0.06 0.06 Xanthan gum 0.04 0.04 Tocopherol 0.0012 0.0012 Table 4: Comparative formulas containing broad-spectrum and UVA screening agents
40 [Table 6]
Percentage ( /0) Fia 3 Fia 4 Fla 5 Fia 6 Fia 7 Ingredients (formula (formula (INCI designation) according according to the to the invention) invention) Aqua 58.948 66.948 57.948 66.948 57.948 Homosalate (UVB solar 9.00 - 9.00 - 9.00 screening agent) Ethylhexyl salicylate (UVB solar screening 4.50 4.50 4.50 4.50 4.50 agent) Butyl methoxydibenzoylmetha ne (UVA solar screening 4.50 4.50 4.50 4.50 4.50 agent) Methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid (1VIAA according to - - - 1.00 1.00 the invention) Methoxyphenylimino dimethylcyclohexene glycine (1VIAA according to the invention) - 1.00 1.00 1.00 1.00 Ethylhexyl methoxycrylene 6.30 6.30 6.30 6.30 6.30 Glycerin 5.00 5.00 5.00 5.00 5.00 Dibutyl adipate 5.00 5.00 5.00 5.00 5.00 Potassium cetyl phosphate 3.00 3.00 3.00 3.00 3.00 Sodium stearoyl glutamate 1.00 1.00 1.00 1.00 1.00 Cetearyl alcohol 0.80 0.80 0.80 0.80 0.80 Pentylene glycol 0.50 0.50 0.50 0.50 0.50
Percentage ( /0) Fia 3 Fia 4 Fla 5 Fia 6 Fia 7 Ingredients (formula (formula (INCI designation) according according to the to the invention) invention) Aqua 58.948 66.948 57.948 66.948 57.948 Homosalate (UVB solar 9.00 - 9.00 - 9.00 screening agent) Ethylhexyl salicylate (UVB solar screening 4.50 4.50 4.50 4.50 4.50 agent) Butyl methoxydibenzoylmetha ne (UVA solar screening 4.50 4.50 4.50 4.50 4.50 agent) Methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid (1VIAA according to - - - 1.00 1.00 the invention) Methoxyphenylimino dimethylcyclohexene glycine (1VIAA according to the invention) - 1.00 1.00 1.00 1.00 Ethylhexyl methoxycrylene 6.30 6.30 6.30 6.30 6.30 Glycerin 5.00 5.00 5.00 5.00 5.00 Dibutyl adipate 5.00 5.00 5.00 5.00 5.00 Potassium cetyl phosphate 3.00 3.00 3.00 3.00 3.00 Sodium stearoyl glutamate 1.00 1.00 1.00 1.00 1.00 Cetearyl alcohol 0.80 0.80 0.80 0.80 0.80 Pentylene glycol 0.50 0.50 0.50 0.50 0.50
41 Hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer 0.396 0.396 0.396 0.396 0.396 Citric acid 0.302 0.302 0.302 0.302 0.302 Caprylyl glycol 0.25 0.25 0.25 0.25 0.25 1,2-hexanediol 0.25 0.25 0.25 0.25 0.25 Xanthan gum 0.20 0.20 0.20 0.20 0.20 Sorbitan isostearate 0.027 0.027 0.027 0.027 0.027 Polysorbate 60 0.027 0.027 0.027 0.027 0.027 Table 6: Comparative formulas containing UVB and UVA screening agents 1V-3 Results and discussion The SPF (sun protection factor) conferred by the different layers is measured:
[Table 7]
Formula Number Average SPF
Standard of plates deviation Theoretical SPF expected for the - 7.5 -4.00% diethylhexyl butamido triazone broad-spectrum screening agent Formulai 3 5.3 0.17 Formula 2 3 21.01 1.01 Table 7: SPF measurements of Formula 1 and Formula 2
[Table 7]
Formula Number Average SPF
Standard of plates deviation Theoretical SPF expected for the - 7.5 -4.00% diethylhexyl butamido triazone broad-spectrum screening agent Formulai 3 5.3 0.17 Formula 2 3 21.01 1.01 Table 7: SPF measurements of Formula 1 and Formula 2
42 [Table 8]
Formula Number Average SPF
Standard of plates deviation Theoretical SPF expected for the 9% 4.6 -homosalate UVB screening agent Formula 3 3 18.62 0.64 Formula 4 3 12.5 0.54 Formula 5 3 24.11 1.49 Formula 6 3 11.73 1.57 Formula 7 3 25.93 1.40 Table 8: SPF measurements from Formula 3 to Formula 7 In the case of tests relating to broad-spectrum screening agents + UVA
screening agent, a very low SPF was obtained for Formula 1 (Fla 1) containing an MAA according to the invention (INCI
designation: methoxyphenylimino dimethylcyclohexene glycine), a UVA screening agent and a broad-spectrum screening agent.
The addition of a second broad-spectrum screening agent made it possible to go from an SPF value of 5 to an SPF value of 21, while the theoretical expected contribution for the broad-spectrum screening agent was 7.5.
For tests relating to UVB +UVA screening agents, the addition of a UVB
screening agent in Formula 4, containing an MAA according to the invention (INCI designation:
methoxyphenylimino dimethylcyclohexene glycine), makes it possible to go from an SPF value of 12.5 at an SPF value of 24.11. The addition of the same screening agent in the same concentration in Formula 6, containing another MAA according to the invention (INCI designation: methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid) makes it possible to go from an SPF value of 11.73 to an SPF value of 25.93.
Formula Number Average SPF
Standard of plates deviation Theoretical SPF expected for the 9% 4.6 -homosalate UVB screening agent Formula 3 3 18.62 0.64 Formula 4 3 12.5 0.54 Formula 5 3 24.11 1.49 Formula 6 3 11.73 1.57 Formula 7 3 25.93 1.40 Table 8: SPF measurements from Formula 3 to Formula 7 In the case of tests relating to broad-spectrum screening agents + UVA
screening agent, a very low SPF was obtained for Formula 1 (Fla 1) containing an MAA according to the invention (INCI
designation: methoxyphenylimino dimethylcyclohexene glycine), a UVA screening agent and a broad-spectrum screening agent.
The addition of a second broad-spectrum screening agent made it possible to go from an SPF value of 5 to an SPF value of 21, while the theoretical expected contribution for the broad-spectrum screening agent was 7.5.
For tests relating to UVB +UVA screening agents, the addition of a UVB
screening agent in Formula 4, containing an MAA according to the invention (INCI designation:
methoxyphenylimino dimethylcyclohexene glycine), makes it possible to go from an SPF value of 12.5 at an SPF value of 24.11. The addition of the same screening agent in the same concentration in Formula 6, containing another MAA according to the invention (INCI designation: methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid) makes it possible to go from an SPF value of 11.73 to an SPF value of 25.93.
43 The expected theoretical contribution for the 9% homosalate UVB screening agent was 4.6.
The comparison between tests 3 and 5, which differ only by the presence of an MAA according to the invention, validates the sun protection amplifier function of the MAA (SPF
18.62 - >24.11).
In conclusion, with an equal protection index, the combinations of screening agents and MAA
according to the invention make it possible to obtain products characterized by a good protection index (SPF > 20), while limiting the introduction of organic screening agents into the formulas thanks to the sun protection amplifier action of MAA.
Thus, the present invention makes it possible to reduce the quantity and concentration of organic screening agents necessary in a sunscreen product, while maintaining a high sun protection factor, i.e., greater than 20. The use of MAAs as anti-UV agents, in combination with organic screening agents, is an eco-compatible solution, eco-responsible for the environment and safe for humans.
Bibliographie references Axelstad M., Boberg J., Hougaard K.S., Christiansen S., Jacobsen P.R., Mandrup K.R., Nellemann C., Lund S.P., Hass U. Effects of pre- and postnatal exposure to the UV-screening agent octyl methoxycinnamate (OMC) on the reproductive, auditory and neurological development of rat offspring. Toxicol. Appl. Pharmacol. 250: 278-90 (2011).
Danovaro R., Bongiorni L., Corinaldesi C., Giovannelli D., Damiani E., Astolfi P., Greci L. Pusceddu A. (2008) Sunscreens cause coral bleaching by promoting viral infections.
Environ Health Perspect 116(4):441-447.
Herzog, B., Mendrok, C. & Mongiat, S., Müller, S, Osterwalder, U. (2003). The Sunscreen Simulator:
A Formulator's Tool to Predict SPF and UVA Parameters. SOFW Journal. 129: 25.
Kinnberg K.L., Petersen G.I., Albrektsen M., Minghlani M., Awad S.M., Holbech B.F., Green J.W., Bjerregaard P., Holbech H. Endocrine-disrupting effect of the ultraviolet screening agent benzophenone-3 in zebrafish, Danio rerio. Environ. Toxicol. Chem. 34: 2833-40 (2015).
The comparison between tests 3 and 5, which differ only by the presence of an MAA according to the invention, validates the sun protection amplifier function of the MAA (SPF
18.62 - >24.11).
In conclusion, with an equal protection index, the combinations of screening agents and MAA
according to the invention make it possible to obtain products characterized by a good protection index (SPF > 20), while limiting the introduction of organic screening agents into the formulas thanks to the sun protection amplifier action of MAA.
Thus, the present invention makes it possible to reduce the quantity and concentration of organic screening agents necessary in a sunscreen product, while maintaining a high sun protection factor, i.e., greater than 20. The use of MAAs as anti-UV agents, in combination with organic screening agents, is an eco-compatible solution, eco-responsible for the environment and safe for humans.
Bibliographie references Axelstad M., Boberg J., Hougaard K.S., Christiansen S., Jacobsen P.R., Mandrup K.R., Nellemann C., Lund S.P., Hass U. Effects of pre- and postnatal exposure to the UV-screening agent octyl methoxycinnamate (OMC) on the reproductive, auditory and neurological development of rat offspring. Toxicol. Appl. Pharmacol. 250: 278-90 (2011).
Danovaro R., Bongiorni L., Corinaldesi C., Giovannelli D., Damiani E., Astolfi P., Greci L. Pusceddu A. (2008) Sunscreens cause coral bleaching by promoting viral infections.
Environ Health Perspect 116(4):441-447.
Herzog, B., Mendrok, C. & Mongiat, S., Müller, S, Osterwalder, U. (2003). The Sunscreen Simulator:
A Formulator's Tool to Predict SPF and UVA Parameters. SOFW Journal. 129: 25.
Kinnberg K.L., Petersen G.I., Albrektsen M., Minghlani M., Awad S.M., Holbech B.F., Green J.W., Bjerregaard P., Holbech H. Endocrine-disrupting effect of the ultraviolet screening agent benzophenone-3 in zebrafish, Danio rerio. Environ. Toxicol. Chem. 34: 2833-40 (2015).
44 Ozàez, I., Morcillo, G., Martinez-Guitarte, J.L. Ultraviolet screening agents differentially impact the expression of key endocrine and stress genes in embryos and larvae of Chironomus riparius. Sci. Total Environ. 557-558: 240-247 (2016).
Petersen, G., Rasmussen, D., Gustavson, K. Study on enhancing the Endocrine Disrupter priority list with a focus on low production volume chemicals Study on enhancing the Endocrine. Revised report to European Commission /DG Environment (2007).
Rehfeld A., et al. Organic Ultraviolet Screening agents Mimic the Action of Progesterone on Human Sperm and Interfere with Sperm Functions. FRI 105-133-Endocrine Disrupting Chemicals and Gene Regulation and Development (posters) (2016).
Schlumpf M., Cotton B., Conscience M., Haller V., Steinmann B., Lichtensteiger W. In vitro and in vivo estrogenicity of UV screens. Environ. Health Perspect. 109: 239-44 (2001).
Schlumpf M., Durrer S., Faass O., Ehnes C., Fuetsch M., Gaille C., Henseler M., Hofkamp L., Maerkel K., Reolon S., Timms B., Tresguerres J.A., Lichtensteiger W. Developmental toxicity of UV screening agents and environmental exposure: a review. Int J Androl. 31: 144-51 (2008).
Szwarcfarb B., Carbone S., Reynoso R., Bollero G., Ponzo O., Moguilevsky J., Scacchi P. Octyl-Methoxycinnamate (OMC), an Ultraviolet (UV) Screening agent, Alters LHRH and Amino Acid Neurotransmitters Release from Hypothalamus of Immature Rats. Exp. Clin.
Endocrinol. Diabetes 116: 94-98 (2008).
Zucchi, S., Blüthgen, N., Ieronimo, A., Fent, K. The UV-Absorber benzophenone-4 alters transcripts of genes involved in hormonal pathways in zebrafish (Danio rerio) eleuthero-embryos and adult males.
Toxicol. Appl. Pharmacol. 250: 137-46 (2011).
Petersen, G., Rasmussen, D., Gustavson, K. Study on enhancing the Endocrine Disrupter priority list with a focus on low production volume chemicals Study on enhancing the Endocrine. Revised report to European Commission /DG Environment (2007).
Rehfeld A., et al. Organic Ultraviolet Screening agents Mimic the Action of Progesterone on Human Sperm and Interfere with Sperm Functions. FRI 105-133-Endocrine Disrupting Chemicals and Gene Regulation and Development (posters) (2016).
Schlumpf M., Cotton B., Conscience M., Haller V., Steinmann B., Lichtensteiger W. In vitro and in vivo estrogenicity of UV screens. Environ. Health Perspect. 109: 239-44 (2001).
Schlumpf M., Durrer S., Faass O., Ehnes C., Fuetsch M., Gaille C., Henseler M., Hofkamp L., Maerkel K., Reolon S., Timms B., Tresguerres J.A., Lichtensteiger W. Developmental toxicity of UV screening agents and environmental exposure: a review. Int J Androl. 31: 144-51 (2008).
Szwarcfarb B., Carbone S., Reynoso R., Bollero G., Ponzo O., Moguilevsky J., Scacchi P. Octyl-Methoxycinnamate (OMC), an Ultraviolet (UV) Screening agent, Alters LHRH and Amino Acid Neurotransmitters Release from Hypothalamus of Immature Rats. Exp. Clin.
Endocrinol. Diabetes 116: 94-98 (2008).
Zucchi, S., Blüthgen, N., Ieronimo, A., Fent, K. The UV-Absorber benzophenone-4 alters transcripts of genes involved in hormonal pathways in zebrafish (Danio rerio) eleuthero-embryos and adult males.
Toxicol. Appl. Pharmacol. 250: 137-46 (2011).
Claims (18)
1. A composition comprising:
¨ at least one amino acid analog of mycosporin called "MAA" selected from the group consisting of molecules A of formula IA or one of its acceptable salts and/or the group consisting of molecules B of formula IB or one of its acceptable salts, said formula IA
being:
and said formula IB being:
for each of the IA and IB formulas, ¨ R1 is hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl;
alkoxy; alkanoyl;
hydroxyl; a sulfo group; a halogen group; a phosphono group; an ester group; a carboxylic acid group; a phenyl group; an amino group; an alkylated fatty acid chain or a polyether;
¨ R2 is alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl; alkoxy;
alkanoyl; a sulfo group; a phosphono group; an ester group; a carboxylic acid group; hydroxyl; or a phenyl group characterized in that it further comprises:
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both UVBs and UVAs;
)23- 12- 14 ¨ at least one organic UVA screening agent.
¨ at least one amino acid analog of mycosporin called "MAA" selected from the group consisting of molecules A of formula IA or one of its acceptable salts and/or the group consisting of molecules B of formula IB or one of its acceptable salts, said formula IA
being:
and said formula IB being:
for each of the IA and IB formulas, ¨ R1 is hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl;
alkoxy; alkanoyl;
hydroxyl; a sulfo group; a halogen group; a phosphono group; an ester group; a carboxylic acid group; a phenyl group; an amino group; an alkylated fatty acid chain or a polyether;
¨ R2 is alkyl; alkenyl; alkynyl; aryl; heterocycle; cycloalkyl; alkoxy;
alkanoyl; a sulfo group; a phosphono group; an ester group; a carboxylic acid group; hydroxyl; or a phenyl group characterized in that it further comprises:
¨ at least two organic screening agents chosen from organic UVB screening agents and/or broad-spectrum organic screening agents absorbing both UVBs and UVAs;
)23- 12- 14 ¨ at least one organic UVA screening agent.
2. The composition according to claim 1, wherein R1 is an alkoxy group of the [CH3]-[CH2],-0-type, wherein "n" is between 0 and 10, preferably "n"=0 or "n"=8.
3. The composition according fo any one of the claims 1 to 2, wherein R2 is a carboxylic acid group of the [COOH]-[CH2],- type, wherein "n" is between 0 and 5, preferably "n"=1 or "n"=0.
4. The composition according to any one of claims 1 to 3, wherein said at least one MAA is selected from the group comprising the following INC1 designations:
methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as the compound corresponding to CAS number 2699128-33-9.
methoxyphenylimino dimethylcyclohexene glycine, caprylyloxyphenylamino dimethyltetrahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylhexahydro benzothiazine carboxylic acid, methoxyphenylimino dimethylcyclohexenyl ethyl glycinate, as well as the compound corresponding to CAS number 2699128-33-9.
5. The composition according to any one of claims 1 to 4, wherein said at least one organic UVA
screening agent is selected from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bi s-(di ethylaminohydroxybenzoyl benzoyl) piperazine, di sodium phenyl dibenzimi dazole tetrasulfonate, in particular butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.
screening agent is selected from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bi s-(di ethylaminohydroxybenzoyl benzoyl) piperazine, di sodium phenyl dibenzimi dazole tetrasulfonate, in particular butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.
6. The composition according to any one of claims 1 to 5, wherein said at least one organic UVB
screening agent is selected from the group comprising the compounds corresponding to the following INCI designations: ethylhexyl salicylate, homosalate, phenylbenzimidazole sulfonic acid and ethylhexyl triazone.
screening agent is selected from the group comprising the compounds corresponding to the following INCI designations: ethylhexyl salicylate, homosalate, phenylbenzimidazole sulfonic acid and ethylhexyl triazone.
7. The composition according to any one of claims 1 to 6, wherein said at least one broad-spectrum organic screening agent is chosen from the group comprising bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, phenylene bis-diphenyltriazine, methylene bis-benzotriazolyl tetramethylbutylphenol and drometrizole trisiloxane, in particular bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylhexyl butamido triazone, tris-biphenyl triazine, methylene bis-benzotriazolyl tetramethylbutylphenol.
8. The composition according to any one of claims 1 to 7, wherein said at least one MAA
represents between 0.1% and 20% by mass relative to the total mass of the composition, preferably between 0.5% and 10%, even more advantageously between 1% and 2%.
represents between 0.1% and 20% by mass relative to the total mass of the composition, preferably between 0.5% and 10%, even more advantageously between 1% and 2%.
9. The composition according to any one of claims 1 to 8, wherein said at least one organic UVB
screening agent represents between 1% and 20% by mass relative to the total mass of the composition, preferably between 2% and 15%.
screening agent represents between 1% and 20% by mass relative to the total mass of the composition, preferably between 2% and 15%.
10. The composition according to any one of claims 1 to 9, wherein said at least one organic UVA
screening agent represents between 1% and 10% by mass relative to the total mass of the composition, preferably between 2% and 7%.
screening agent represents between 1% and 10% by mass relative to the total mass of the composition, preferably between 2% and 7%.
11. The composition according to any one of claims 1 to 10, wherein said at least one broad-spectrum organic screening agent absorbing both UVBs and UVAs represents between 1% and 15%
by mass relative to the total mass of the composition, preferably between 2%
and 10%.
by mass relative to the total mass of the composition, preferably between 2%
and 10%.
12. The composition according to any one of claims 1 to 11, wherein the composition comprises:
¨ at least two organic UVB screening agents;
¨ at least one organic UVA screening agent.
¨ at least two organic UVB screening agents;
¨ at least one organic UVA screening agent.
13. The composition according to any one of claims 1 to 12, wherein the composition comprises:
¨ at least two broad-spectrum organic screening agents absorbing both UVBs and UVAs;
¨ at least one organic UVA screening agent.
¨ at least two broad-spectrum organic screening agents absorbing both UVBs and UVAs;
¨ at least one organic UVA screening agent.
14. The cornposition according to any one of claims 1 to 13, wherein the composition comprises:
¨ at least UVB screening agents corresponding to the following INCI
designations: octyl salicylate and homosalate;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
butyl methoxydibenzoylmethane.
¨ at least UVB screening agents corresponding to the following INCI
designations: octyl salicylate and homosalate;
¨ at least the organic UVA screening agent corresponding to the following INCI designation:
butyl methoxydibenzoylmethane.
15. The composition according to any one of claims 1 to 14, wherein the composition comprises:
¨ at least broad-spectrum screening agents absorbing both UVBs and UVAs corresponding to the following INCI designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least one UVA solar screening agent chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, in particular butyl rnethoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate, advantageously butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.
¨ at least broad-spectrum screening agents absorbing both UVBs and UVAs corresponding to the following INCI designations: diethylhexyl butamido triazone and bis-ethylhexyloxyphenol methoxyphenyl triazine;
¨ at least one UVA solar screening agent chosen from the group comprising the compounds corresponding to the following INCI designations: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, bis-(diethylaminohydroxybenzoyl benzoyl) piperazine, disodium phenyl dibenzimidazole tetrasulfonate, in particular butyl rnethoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate, advantageously butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate.
16. The composition according to any one of claims 1 to 15, wherein the composition is free from solar screening agents corresponding to the following INCI designations: 4-methylbenzylidene camphor, 3-methylbenzylidene camphor, benzophenone-2, benzophenone-3, benzophenone-4, ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, octocrylene, octyl dimethyl PABA.
17. The composition according to any one of claims 1 to 16, wherein the composition has a sun protection factor called "SPF" equal to or greater than 20, advantageously equal to or greater than 30, preferably equal to or greater than 40, or even equal to or greater than 50.
18. The composition according to any one of claims 1 to 17, for its use for protection against solar radiation, in particular of wavelength between 100 and 400 nm.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR2107441 | 2021-07-08 | ||
FR2107441A FR3124945A1 (fr) | 2021-07-08 | 2021-07-08 | Composition cosmetique solaire contenant des acides amines analogues de la mycosporine |
PCT/FR2022/051365 WO2023281224A1 (fr) | 2021-07-08 | 2022-07-07 | Composition cosmetique solaire contenant des acides amines analogues de la mycosporine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3222853A1 true CA3222853A1 (fr) | 2023-01-12 |
Family
ID=78536289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3222853A Pending CA3222853A1 (fr) | 2021-07-08 | 2022-07-07 | Composition cosmetique solaire contenant des acides amines analogues de la mycosporine |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4366686A1 (fr) |
KR (1) | KR20240032736A (fr) |
CN (1) | CN117529303A (fr) |
BR (1) | BR112023025482A2 (fr) |
CA (1) | CA3222853A1 (fr) |
FR (1) | FR3124945A1 (fr) |
WO (1) | WO2023281224A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024027927A1 (fr) * | 2022-08-05 | 2024-02-08 | Symrise Ag | Composition avec fps et photoprotection contre les uva améliorés |
WO2024027930A1 (fr) * | 2022-08-05 | 2024-02-08 | Symrise Ag | Compositions comprenant un agent renforçateur antimicrobien |
WO2024027926A1 (fr) * | 2022-08-05 | 2024-02-08 | Symrise Ag | Composition comprenant un stabilisant de filtre uv |
WO2024027929A1 (fr) * | 2022-08-05 | 2024-02-08 | Symrise Ag | Composition avec résistance à l'eau améliorée |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0028161D0 (en) * | 2000-11-17 | 2001-01-03 | Natural Environment Res | Personal care compositions |
FR2865398B1 (fr) | 2004-01-23 | 2009-07-03 | Jean Noel Thorel | Compositions destinees a la protection cellulaire vis-a-vis des uva, de la peau, et/ou des phaneres. |
WO2008029064A2 (fr) | 2006-09-06 | 2008-03-13 | Thorel Jean-Noel | Utilisation topique d'un extrait peptidique de soja et/ou de ble comme agent photoprotecteur |
US9487474B2 (en) * | 2012-06-04 | 2016-11-08 | Elkimia, Inc. | Imino compounds as protecting agents against ultraviolet radiations |
ES2550374B1 (es) * | 2015-06-30 | 2016-09-08 | Universidad De La Rioja | Compuestos fotoprotectores análogos de MAA, procedimiento de síntesis y composición que comprende los mismos |
-
2021
- 2021-07-08 FR FR2107441A patent/FR3124945A1/fr active Pending
-
2022
- 2022-07-07 KR KR1020237043361A patent/KR20240032736A/ko unknown
- 2022-07-07 CN CN202280043676.1A patent/CN117529303A/zh active Pending
- 2022-07-07 BR BR112023025482A patent/BR112023025482A2/pt unknown
- 2022-07-07 WO PCT/FR2022/051365 patent/WO2023281224A1/fr active Application Filing
- 2022-07-07 EP EP22751136.7A patent/EP4366686A1/fr active Pending
- 2022-07-07 CA CA3222853A patent/CA3222853A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
CN117529303A (zh) | 2024-02-06 |
BR112023025482A2 (pt) | 2024-02-27 |
FR3124945A1 (fr) | 2023-01-13 |
EP4366686A1 (fr) | 2024-05-15 |
KR20240032736A (ko) | 2024-03-12 |
WO2023281224A1 (fr) | 2023-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3222853A1 (fr) | Composition cosmetique solaire contenant des acides amines analogues de la mycosporine | |
WO2020204191A1 (fr) | Produit cosmétique contenant une substance de conversion de longueur d'onde ultraviolette et agent médicinal | |
EP3714865B1 (fr) | Composition cosmetique solaire a haute teneur en filtres solaires derives de triazine | |
BRPI0721862B1 (pt) | preparação compreendendo sais solúveis estáveis de ácido fenilbenzimidazol sulfônico, e uso de aminoácidos básicos | |
BRPI0721945A2 (pt) | Uso de troxerutina para extinguir a fluorescência do fenil dibenzimidazol tetrassulfonato de dissódio | |
BR112019012282A2 (pt) | método para aprimorar as propriedades sensoriais de emulsões de óleo em água | |
BRPI0612695A2 (pt) | composição para autobronzeamento sem ação do sol e método de autobronzeamento sem ação do sol | |
ES2523305T5 (es) | Composiciones y métodos para la piel y el cabello | |
EP3818973B1 (fr) | Composition solaire resistante a l'eau a haute teneur de triazines | |
KR20170132855A (ko) | 인간 피부 세포주를 향한 청색광에 대한 루테인의 보호 작용 | |
CN1933801A (zh) | (2-羟苯基)醇的用途和含有该化合物的化妆品或治疗制剂 | |
CN106619167A (zh) | 一种美白提亮组合物、制备方法和在化妆品中的应用 | |
KR20120107944A (ko) | 피부 라이트닝을 위한 테트라펩티드 | |
US20190374454A1 (en) | Oxybenzone-free compositions | |
WO2007135197A2 (fr) | Utilisation de benzophénone-4 et de ses sels pour éteindre la fluorescence du phényl-dibenzimidazole-tétrasulfonate disodique | |
JP4326512B2 (ja) | 美白剤及びこれを含有する美白化粧料 | |
EP3466419B1 (fr) | Utilisation du trimethoxybenzyl acetylsinapate, avantageusement en combinaison avec au moins un filtre solaire, pour la protection de la peau | |
FR3091652A1 (fr) | Composition topique solaire protectrice de la peau exposee a l’irradiation de la lumiere visible a haute energie | |
FR3091649A1 (fr) | Composition cosmetique ou pharmaceutique permettant de reduire l’immunosuppression induite par une exposition au rayonnement ultraviolet | |
WO2015011311A1 (fr) | Combinaison pour réduire l'hyperpigmentation de la peau | |
KR20190023651A (ko) | 피부미백용 조성물 | |
BR102017014814A2 (pt) | Composições tingidas de filtro solar com controle de oleosidade | |
WO2024003594A1 (fr) | Compositions de soins personnels comprenant du pancratium maritimum | |
WO2020204196A1 (fr) | Composition d'émulsion comprenant une substance de conversion de longueur d'onde ultraviolette et un épaississant de phase huileuse organique | |
CA2515840A1 (fr) | Composition photoprotectrice contenant un derive de 1,3,5-triazine, un derive du dibenzoylmethane, et un compose bis-resorcinyl triazine |